THE JOURNAL OF IMMUNOLOGY
Copyright © 1983 by The American Association of Immunologists
Vol. 130, No. 6, June 1983
Printed in U.S.A.

AUTHOR INDEX TO VOLUME 130

Aalberse, Rob C., 722
Abo, Toru, 1171
Abraham, Sam, 2133
Abrass, Christine K., 195
Accolla, Roberto S., 283
Acha-Orbea, Hans, 2952
Acuto, Oreste, 2142
Adamson, Thomas C., III., 203
Adler-Storthz, Karen, 1943
Ahmed, Aftab, 15, 632, 2574
Aihara, Yukoh, 2920
Aikawa, Masamichi, 428
Ajioka, Richard S., 2974
Akiyama, Hideki, 1759
Alexander, Hannah, 1401
Allen, Paul M., 661
Allison, James P., 471
Alpert, Stephen E., 102
Altman, Amnon, 169
Alving, Carl R., 1390, 2886
Ames, Robert S., 303
Amos, D. Bernard, 1863
Amsbaugh, Diana F., 19
Amsden, Adele, 579, 586
Anderson, Kenneth C., 1132
Anderson, Sylvia L., 1019
Aoki, Ichiro, 2413
Aoyagi, Shoko, 2903
Appella, Ettore, 463
Apte, Ron N., 1814
Arbogast, Daniel N., 1695
Archibald, Anna C., 2324
Aronson, Judith, 1390
Asano, Yoshihiro, 67, 1061
Ascher, Nancy L., 1610
Asherson, Geoffrey L., 785
Ashman, Robert F., 2568
Askenase, Philip W., 2104
Asofsky, Richard, 2027, 2287
Atkins, Fred M., 341
Atkinson, John P., 834
Auböck, Josef, 2008
Auerbach, Harvey S., 102
Austen, K. Frank, 1885, 1891
Ayoub, Elia M., 932

Ba, Denian, 501
Bach, F. H., 2261, 2499
Bach, Fritz H., 542, 1556, 1764
Bach, Jean-François, 777, 1195, 2467
Bacon, Larry D., 1007
Badaracco, Gianfranco, 1622
Baine, Yaela, 1478
Baine, Yaella, 15
Baker, Phillip J., 15
Baker, Susan S., 2856
Bakke, Antony C., 2651
Balazs, Ivan, 1231
Balcerzak, Stanley P., 365
Balch, Charles M., 1171
Balderas, Robert S., 2161
Ball, Edward D., 2937
Bankhurst, Arthur D., 1215, 1658
Barker, Clyde F., 2168
Barnes, Mary Carol, 457
Barr, I. G., 115
Barr, Linda, 2837
Barrios, Hebe A., 1600
Bartal, Arie H., 1019
Basham, Teresa Y., 1492
Bass, David A., 1910
Basta, Patricia, 2423
Bates, Michael P., 1132
Battisto, Jack R., 533, 2557, 2561
Battye, Frank, 558
Batuman, Olcay A., 1051
Bauer, Johann, 839
Baum, Linda L., 2121
Baxevanis, Constantin N., 1498
Beaman, Blaine L., 2401
Beckman, Karla D., 2557, 2561
Beebe, Deborah P., 1317
Befus, A. Dean, 435
Beisel, Kirk, 885
Bellanti, Joseph A., 518
Bellgrau, Donald, 2005, 2168
Bellone, Clifford J., 2519
Benacerraf, Baruj, 457, 506
Bender, James G., 2316
Benike, Claudia J., 2623
Ben-Nun, Avraham, 1205
Benson, Herbert, 694
Berden, Jo H. M., 1699
Berger, Melvin, 1021
Bernard, Claude C. A., 2675
Bernhard, Eric J., 2974
Bernhard, Michael I., 1451
Berti, Brunilde, 903
Bettens, F., 1770
Bevan, Michael J., 1780
Beveridge, Richard, 2947
Bhan, Atul K., 2615
Bhattacharjee, Apurba K., 1012
Biasi, Giovanni, 1447
Biddison, William E., 1856, 2629
Bigotti, Aldo, 1462
Birch, Ruth E., 1706
Birshtein, Barbara K., 1967
Bitoh, Soji, 1038
Bitter-Suermann, Dieter, 1345, 2861
Björck, L., 297
Blalock, J. Edwin, 773
Blank, Kenneth J., 2236
Bloom, Barry R., 649
Boggs, Joan M., 1687
Boldt, David H., 1646
Bona, Constantin, 1819
Bonavida, Benjamin, 2479, 2960, 2965
Bonnard, Guy D., 667, 768
Boraschi, Diana, 903
Bordin, Sandra, 1871
Borel, Yves, 157
Boros, Dov L., 418, 423
Borsos, Tibor, 1012, 2825
Borysenko, Joan Z., 694
Borysenko, Myrin, 334, 694
Bostick-Bruton, Frieda, 2666
Boyd, Andrew W., 2046
Bradley, J. Garrett, 1833
Brandhorst, Jane S., 2987
Brandriss, Michael W., 2915
Braun, Jonathan, 2113
Breit, Samuel N., 681
Breviario, Diego, 1622
Briggs, Carlton J., 1323
Briles, David E., 2423, 2871
Britt, William J., 2363
Britz, Judith S., 1848
Brock, Mary A., 2586
Bromberg, Jonathan S., 2250
Brookmeyer, Ronald, 1512
Brown, Eric, 845
Brown, Eric J., 2825
Brown, Joseph P., 1467
Brunda, Michael J., 1974
Buchmeier, Michael J., 912
Buckingham, Bruce, 1189
Buckley, Rebecca H., 1182
Bucy, R. P., 2062
Burakoff, Steven J., 493
Burge, Joseph, 2656
Burgio, G. Roberto, 1129
Burmester, Gerd R., 145
Burns, Gordon F., 2442
Burstin, Stuart J., 2915
Burton, Robert C., 951
Butcher, Eugene C., 1097
Butler, Joseph L., 165
Bykowsky, Michael J., 2093

Cabana, Veneracion G., 1736
Cabasco, Lydia, 1467
Cabirac, Gary F., 399
Caillol, Danielle H., 1432
Caldes, George, 19
Callahan, Gerald N., 471
Cambier, John C., 626, 1247
Camerini-Otero, R. Daniel, 463
Campbell, Ann E., 490
Cantor, Harvey, 1743
Caraux, Jean, 2295
Carlson, George A., 484
Carlsson, Sven R., 1837
Carnaud, Claude, 777
Carney, Walter P., 390
Caro, Jaime, 1051
Carrel, S., 2456
Carson, Dennis A., 162, 169
Carter, Robert H., 997
Castellanos, R. Cano, 121
Caulfield, Michael J., 1774
Cavaliere, Renato, 1462
Ceredig, Rhodri, 33, 546
Cerf-Bensussan, Nadine, 2615
Cerottini, Jean-Charles, 24
Chan, Marcia, 925
Chan, Marion M., 2075
Chandler, Phillip, 785
Chang, Jin-Lai, 269
Chapman, Harold A, Jr., 261
Charles, M. Arthur, 1189
Chase, Catharine M., 951
Chen, Ben D.-M., 2256
Chensue, Stephen W., 423
Chesebro, Bruce, 2363
Chess, Leonard, 698
Cheung, Kee, 2324
Cheung, Margaret K., 1231
Chichehian, Behrouz, 2295
Chien, Millie M., 2568
Chin, Terry W., 173
Chisari, Francis V., 1395, 1401
Choi, Yong Sung, 527
Chou, C.-H. J., 2180, 2183
Chou, C.-H. Jen, 191
Chou, C.-H Jen, 1024
Chu, Edward T., 2002
Chused, Thomas M., 1200
Ciobanu, N., 2644
Circolo, Antonella, 1012
Claflin, J. Latham, 2871
Claman, Henry N., 56
Clancy, Robert L., 2117
Clanton, Jeffrey A., 1356
Clark, Brian R., 2302
Clark, David, 925
Clark, Edward A., 2448
Clement, Loran T., 2763
Cogburn, Larry A., 2109
Cohen, Harvey J., 2856
Cohen, Lawrence K., 919
Cohen, Philip L., 181
Cohn, Allen L., 2969
Cole, F. Sessions, 102
Coleman, David L., 2195
Coleman, Mary Sue, 365
Colizzi, Vittorio, 785
Collavo, Dino, 1447
Colle, E., 1732
Colley, Daniel G. 1356, 2691
Collins, Linda A., 370
Colombani, J., 297
Colten, Harvey R., 102
Cone, Robert E., 2083
Conlon, Paul J., 222
Conrad, Daniel H., 327, 2357
Conta, Barbara S., 2231
Cook, Richard G., 1293
Cooke, Anne, 1071
Coonrod, J. Donald, 2589
Cooper, Max D., 671, 1668
Cooper, Neil R., 1317
Corbell, Lynette B., 399
Corey, E. J., 1885
Costa, Max, 1924
Crabb, Joseph H., 2407
Crary, Bruce, 694
Crawford, Frances G., 2308
Cresswell, Peter, 1863
Cripps, Allan W., 2117
Cudkowicz, Gustavo, 1980
Cudowicz, Gustavo, 2429
Culwell, Alan R., 1947
Cummings, David E., 33
Cunningham, Anthony L., 2397
Czitrom, Andrei A., 546

Dahinden, Clemens, 857, 863
Dang, Howard, 2782
Daniel, Sylvester, 2908
Dardenne, Mireille, 1195
Darrow, Timothy L., 2982
David, Peter H., 2886
Davis, Mary L., 2525
Day, Eugene D., 1687
Day, Terrilee T., 1695
Daynes, Raymond A., 1536, 2974
Dayton, Elahe Talieh, 1120
Dazzi, Francesco, 1447
De Baetselier, Patrick, 1017
DeChatelet, Lawrence R., 1910
Deelder, André M., 1
Deem, Richard L., 2401
de Hoop, Job, 655
Delovitch, Terry L., 2241, 2250
DeMaeyer, Edward, 2392
DeMaeyer-Guignard, Jaqueline, 2392
Dempsey, Walla L., 405, 2896
De Rossi, Anita, 1447
Derry, Helen R., 63
Devaux, Christian, 2786
Devens, Bruce H., 993
de Waal, Leo P., 655, 1090
deWeck, A. L., 1770
de Weger, Roel A., 2348
Diamantstein, Tibor, 51
Diehl, Volker, 2666
Diggs, Carter L., 1390
Dimitriu-Bona, Alexandra, 145
Dinarello, Charles A., 890, 2708
Di Pauli, Raimund, 2732
Discipio, Richard G., 2605
Dixon, Frank J., 1699, 2161
Djeu, Julia Y., 2908
Dobos, Claraine B., 538
Dodson, Leonard E., 1189
Domzig, Wolfgang, 1970
Donnenberg, Albert D., 717
Donohue, John H., 2203
Dorey, Fredrick, 818
Dorf, Martin E., 1274, 1604, 2413
Dorsey, Sheryl A., 1646
Dougherty, Suanne F., 1784
Doughty, Floyd A., 2401
Dower, Steven K., 130, 138
Dray, Sheldon, 267
Drebin, Jeffrey A., 506, 997
Dreesman, Gordon R., 173, 385, 1943, 1947
Dreher, Kevin L., 442
Dresden, Marc H., 1
Dröge, Wulf, 2214, 2508
Dubey, Devendra, 1678
Dubey, Devendra P., 524
Dumont, Francis J., 1843
Dupont, Bo, 2635, 2644
Duprez, Veronique, 493
Durant, Debra A., 2727
Dy, M., 1937
Dy, Michel, 2343
Dynesius-Trantham, Roselynn A., 2689

Eardley, Diane D., 2209
Echalier, G., 297
Edson, Clark M., 919
Ehlin-Henriksson, Barbro, 1985, 2448
Eichmann, Klaus, 7
Eiklid, Dristen, 380
Eisenbarth, George S., 1182
Ejzemberg, Regina, 2825
Elder, Melissa E., 1723
Elgas, Laurie J., 1495
Elkins, Karen, 1247
Elliott, Bruce E., 1426
Eliner, Jerrold J., 2484
El-Sadr, Wafaa M., 428
Ely, John M., 2798
Emam, Monsoor, 1536
Endres, Robert O., 781
Engers, Howard D., 24
Engleman, Edgar G., 1288, 2623
English, Denis, 850
English, Kerry E., 1210
Ennis, Francis A., 2908
Evans, Glen A., 463, 2418, 2514
Evans, Robert, 1663, 2511
Evans, Robert L., 2623
Ewert, Donald, 2368

Faanes, Ronald B., 527
Falk, Werner, 2214, 2508
Falkenberg, Frank W., 1719
Fan, David P., 756, 2386
Fanger, Michael W., 2937
Fanning, Virginia, 2133, 2142
Fantone, Joseph C., 1495
Farram, Eunice, 1252, 2743, 2750
Farrar, John, 2219
Fasano, Mary B., 1376
Fauci, Anthony S., 165, 678, 2663
Faust, Jeffrey, 2142
Favreau, C., 254
Fearon, Douglas T., 370, 1668, 1891
Fehr, Jorg, 857, 863
Feighny, Robert J., 1303, 1309
Feit, Carl, 1019
Feldman, Joseph D., 1236, 1754
Feldman, Michael, 1017
Feldman, S., 2644
Ferrone, Soldano, 1462
Fieser, Terry M., 2161
Finbloom, David S., 1210, 1489
Findlay, S. R., 1997
Findlay, Steven R., 334
Finke, James H., 763
Finkelman, Fred D., 350, 619, 2534
Fiorini, Gianfrancesco, 1622
Fischback, Michael, 2782
Fischer, Dina G., 1220
Fischer, Elizabeth, 2821
Fischetti, Vincent A., 896
Fisher, Cheryl A., 2471
Fisher, Melissa, 1573, 1580
Fisher, Murray M., 1176
Fisher, Richard I., 2666
Fitch, Frank W., 2461, 2798
Fitzgerald, Patricia A., 1663
Flaherty, Lorraine, 1293
Fleischer, Bernhard, 2187
Fleisher, Thomas A., 1021
Fletcher, Mark P., 1902
Flieger, Nanette, 946
Flomenberg, Neal, 2635, 2644
Foiles, Peter G., 1043
Foley, F. Lamar, 490
Fong, Sherman, 162
Foon, Kenneth A., 1451
Fowler, Elizabeth, 1303, 1309
Fox, Robert I., 203
Fraillon, D., 115
Frank, Michael, 845
Fredericksen, Tommy L., 2528
Freed, John H., 2277
Friedenson, Bernard, 362
Friedman, Marc M., 341
Friedman, Steven M., 1164
Frisman, Dennis M., 203
Fritz, Robert B., 191, 1024, 2180, 2183
Froelich, Christopher J., 1658
Fuchs, Dietmar, 1047
Fujii, Nobuhiro, 1683
Fujimoto, Shigeyoshi, 1038
Fukunaga, Kenichi, 1241
Fulop, Gabrielle, 644
Funatsu, Gunki, 2903
Funder, J. W., 115
Furukawa, Fukumi, 740

Gajl-Peczalska, Kazimiera J., 1159
Galanos, Chris, 857
Galili, N., 121
Galili, U., 121
Gallin, John I., 1902
Gandour, Donna M., 1108
Ganea, Doina, 267
Gans, Paula J., 800
Garchon, Henri-Jean, 777
Garman, Richard D, 756
Garovoy, Marvin R., 357
Garrigues, H. Jacques, 1467
Gartland, G. Larry, 1668
Gastinel, Louis-Noël, 1195
Gately, Celia L., 1226
Gatenby, Paul A., 2623
Gates, Frederick T., III, 442
Gautam, Subhash C., 533, 2557
Gazzinelli, Giovanni, 2891
Gearhart, Patricia J., 313
Gebel, Howard M., 29
Geczy, Carolyn L., 2743, 2750
Geha, Raif S., 242, 524, 1634, 1678, 2002, 2493
Gelfand, Erwin W., 45
Gemsa, Diethard, 2861
Gendler, Simona, 2651
Gerhard, Walter, 2379
Germain, Ronald N., 457
Gershon, Richard K., 2083
Gewurz, Henry, 1736, 2121, 2809
Giacomini, Patrizio, 1462
Giedlin, Martin A., 471
Gillis, Steven, 222, 712, 763, 2651
Gilman, Steven C., 1236, 1754
Gilmour, Douglas G., 2528
Ginelli, Enrico, 1622
Ginsburger-Vogel, Thomas, 297
Giovanniello, Octavio A., 1600
Girardet, C., 2456
Gitler, Carlos, 2886
Glasebrook, Andrew L., 546, 1545, 1552
Glassock, Richard J., 195
Glaudemans, Cornelis P. J., 1012
Gleichmann, Ernst, 209, 2693
Gleichmann, Helga, 209, 655
Glick, Bruce, 2109
Glimcher, Laurie H., 2287
Golden, Michael, 1189
Golding, Basil, 1043
Golding, Hana, 1043
Goldstein, Allan L., 791, 1182
Goldstein, Gideon, 698
Golightly, Marc G., 1220
Golstein, Pierre, 1432
Gonwa, Thomas A., 706
Good, Michael F., 78, 2046
Gooding, Linda R., 2418
Goodman, Michael G., 551, 2042, 2580
Gorczynski, Reginald M., 2241
Gordon, John, 970
Gordon, Julius, 644
Goroff, Diane K., 2882
Goto, Toshio, 1350
Gougeon, Marie-Lise, 1521
Goyert, Sanna M., 706
Grady, Stafford, 2002
Granfors, Kaisa, 2038
Granger, Gale A., 2479
Granstein, Richard D., 2099
Gray, Patrick W., 2011
Graziano, Robert F., 2937
Greene, Bruce M., 428
Greene, Mark I., 506, 997, 2250
Greenspan, John S., 1713
Gregg, Sheryl L., 1159
Greiner, Dale L., 2798
Grever, Michael R., 365
Griffin, James D., 2947
Griffiss, J. McLeod, 2882
Griffiths, Gillian M., 937
Grimm, Elizabeth A., 958
Grol, Michael, 323
Gromkowski, Stanislaw, H., 2546
Groscurth, Peter, 2952
Grossman, Nili, 1867
Groux, Brigitte, 86
Grumet, F. Carl, 1288
Guerne, Pierre-André, 2225
Guimezanes, Annick, 1540
Gunn, Han C., 1071
Guthman, David A., 2837
Guttmann, R. D., 1732

Habbersett, Robert C., 1843
Hackett, Charles, 2379
Hadding, Ulrich, 1345, 2861
Hall, Nicholas R., 791
Hamann, Ute, 7
Hamano, Teruaki, 2027, 2287
Hamaoka, Toshiyuki, 2219
Hamburger, J., 1937
Hamlyn, Pamela H., 937
Hammer, Carl, 845
Hammer, Carl H., 2825
Hämmerling, Ulrich, 2075
Hanaoka, Masao, 2720
Hancock, Kathy, 1359, 1366
Handa, Kazuko, 981, 988
Hang, LeMing, 1699
Hanna, Michael G., Jr., 1451, 2987
Hanna, Nabil, 974
Hannum, Charles, 1527
Hansen, Barbara, 2121
Hansen, Ted H., 1843
Hanson, Daniel F., 216
Hanto, Douglas W., 1610
Harbeck, Ronald J., 1695
Hardy, Russell, 1132

Harrison, David E., 484
Hart, Gerald W., 1848
Hartung, Hans-Peter, 1345, 2861
Hashim, George A., 1687
Haskins, Kathryn M., 1033
Hassner, Avi, 1569
Hauptman, Stephen P., 1051
Hausen, Arno, 1047
Hayes, Roberta L., 56
Haynes, Barton F., 1182
Heagy, Wyrta, 2546
Hedrick, Stephen M., 1527, 1958
Hefeneider, Steven H., 222
Heiner, Douglas C., 1654
Hellström, Ingegerd, 1467
Hellström, Karl Erik, 1467
Henderson, Frederick W., 1182
Hengartner, Hans, 2952
Henkel, Richard D., 1943
Henle, Werner, 919
Henney, Christopher S., 222
Hensley, Lucinda L., 1182
Henson, P. M., 1997
Herberman, R. B., 768
Herberman, Ronald B., 228, 1350, 1970
Hercend, Thierry, 2947
Hersh, Evan M., 1500
Herzenberg, Leonard A., 1967
Hess, Allan D., 717
Heumann, D., 2456
Hibbs, John B., Jr., 261
Hilfiker, Mary L., 533, 763, 1774
Hinrichs, James, 829
Hinuma, Yorio, 2942
Hirano, Takao, 1300
Hirashima, Mitsuomi, 878
Hirata, Fusao, 878, 1930
Hirayama, Nakami, 1300
Hirose, Sachiko, 740
Hirsch, Martin S., 390
Hirshaut, Yashar, 1019
Hirvonen, Toivo, 153
Ho, May-Kin, 108
Hodes, Richard J., 67, 1061
Hoffman, Rosemary A., 1610
Hoffman, Steven A., 1695
Hoffmann, Michael K., 2075
Hofstetter, Mark, 1376
Holda, James H., 732
Holden, Howard T., 1974
Holdsworth, Stephen R., 735
Hollinger, F. Blaine, 173
Homma, Yoshimi, 2849
Hooks, John J., 1784
Hoover, Dennis, 1885
Hoover, Richard G., 521
Hopper, Kelvin, 2750
Horgan, Carol, 2656
Horwitz, David A., 2651
Howard, Maureen, 2219
Howell, Frank V., 203
Howlett, Geoffrey J., 1313
Hoyer, Lawrence C., 1451
Hsu, Angela, 1790
Hsu, Shin, 2256
Huang, Kun-yen, 791
Huber, Christoph, 1047
Hudson, Diana E., 2886
Huff, Thomas F., 1802
Hugli, Tony E., 1257, 1891, 2605
Hui, Kam M., 596
Hunt, Pamela, 1439
Hurme, M., 1077
Hurtenbach, Ursula, 1561
Husband, Alan J., 2117
Hutchings, Patricia R., 1071
Hutt-Fletcher, Lindsey M., 1303, 1309

Iacoviello, Vito, 390
Iida, Kyoko, 1876
Iijima, Masafumi, 1586
Imai, Kenji, 2552
Imai, Mitsunobu, 2903
Imokawa, Minoru, 187
Inada, Tetsushi, 1300
Inverso, Jill A., 412
Ionescu-Matiu, Irina, 1947
Isakov, Noah, 1017
Ishizaka, Akihito, 1056
Ishizaka, Kimishige, 649, 878, 1802, 2357
Ishizaka, Teruko, 327, 2357
Itoh, Kyogo, 981
Iwata, Makoto, 1802, 1930

Jackson, David C., 1313
Jacobs, Roberta J., 2775
Jadus, Martin R., 2067
Jagielski, Pawel, 1159
Jalkanen, Markku, 2038
Jalkanen, Sirpa, 2036
James, Karen, 2121
Jasin, Hugo E., 1918
Jayaraman, Sundararajan, 2519
Jelinek, Diane F., 2597
Jenkins, Robert N., 1293
Jensen, Pamela J., 2071
Johnson, Howard M., 773, 2011
Johnson, Robert J., 2930
Johnson, Robert M., 2866
Joiner, Keith, 845, 1881
Jones, Patricia P., 449
Jonsson, Viggo, 2448
Jordan, Bertrand R., 1432
Ju, Shyr-Te, 1274
Julian, Christine, 91
Juliano, Rudolph L., 1500
Jyonouchi, Harumi, 1616

Kaartinen, Matti, 937
Kabelitz, Dieter, 2505
Kahle, Robert, 2479
Kai, Chieko, 2814
Kaieda, Takeji, 1241
Kaiser, N., 121
Kaliner, Michael, 1881, 2837
Kaminsky, Steven G., 1980
Kammer, Gary M., 38, 1706
Kamoun, P., 1937
Kanagawa, Osami, 24
Kanellopoulos-Langevin, Colette, 350
Kaneoka, Hidetoshi, 1280
Kannagi, Mari, 2942
Kanno, Masamoto, 2552
Kapp, Judith A., 565, 2062
Kappler, John, 1033
Kappler, John W., 781, 2088
Karjalainen, Klaus, 937
Karush, Fred, 313
Kasahara, Marleen S., 1891
Kasahara, Tadashi, 1784
Kasakura, Shinpei, 2720
Kasper, Lloyd H., 2407
Kast, Wybe M., 1090
Kater, Louis, 2348
Kato, Fujiko, 1683
Katoh, Kiyoshi, 2920
Katona, Ildy M., 350
Katz, Allan, 1176
Katz, Naftale, 2891
Katz, Stephen P., 1381, 1386
Katzav, Shulamit, 1017
Kaufman, James F., 808
Kaufman, Kateryna, 2241, 2250
Kay, H. David, 475
Kazatchkine, Michel D., 2821
Kearney, John F., 2423
Keller, Margaret A., 1654
Kelly, Mary A., 1359, 1366
Kelso, Anne, 546, 1545
Kennedy, Ronald C., 385, 1943, 1947
Kenny, James J., 2574
Kernan, N., 2644
Kershnar, Ann, 1189
Key, Marc E., 1451, 2987
Khalid, B. A. K., 115
Kidd, Rose M., 1654
Kierszenbaum, Felipe, 908
Kiesel, Ulrich, 1719
Kiley, Susan C., 2908
Kim, Byung S., 596
Kimura, Arthur K., 2056
Kimura, Hiromitsu, 2168
Kimura, Shoji, 2075
Kincade, Paul W., 1616
Kindt, Thomas J., 442
King, Donna P., 449
King, Maurice G., 2117
Kinsky, Stephen C., 781
Kirkpatrick, D., 2644
Kirkpatrick, Dahlia, 1663
Kishimoto, Susumu, 1056, 1241
Kishimoto, Tadamitsu, 1056, 1241
Kitridou, Rodanthi C., 2651
Kitz, Dennis, 829
Klein, George, 1985, 2448, 2899
Klein, Jan, 1280, 1498, 2926
Klein, John R., 1780
Klein, Michel H., 1176
Klimpel, Gary R., 1084
Klimpel, Kathleen D., 1084
Kobatake, Shinzo, 1056
Kobayashi, George, 829
Kobayashi, Hiroshi, 501
Koga, Yutaka, 501
Kohno, Shigeru, 2675
Kojima, Somei, 1300
Kolb, Hubert, 1719
Kolb, William P., 1871
Koller, Beverly, 1833
Komatsu, Toshinori, 579, 586
Koren, Hillel S., 1226
Korkesh, A., 121
Korngold, Robert, 2236
Kostyu, Donna D., 1863
Kourilsky, François M., 1432
Kraal, Georg, 1097
Krammer, Peter H., 7, 2502
Krangel, Michael S., 1856
Kresina, Thomas F., 1478
Kreth, Hans W., 2187
Kripke, Margaret L., 2099
Kristensen, F., 1770
Krueger, Gerald G., 1536
Kruger, G., 2644
Kruisbeek, Ada M., 1027
Kubagawa, Hiromi, 671, 2423
Kumagai, Jun-Ichi, 1759
Kumagai, Katsuo, 981, 988
Kunkel, Henry G., 2505
Kuo, Mei-chang, 442
Kupinski, John M., 2277
Kurata, Sunnichi, 496
Kuritani, Taro, 671
Kushnir, Ella, 781
Kusnecov, Alexander W., 2117
Kutz, Ilan, 694
Kuusela, Pentti, 1809
Kyeyune-Nyombi, Eru, 791

La Forest, Ann C., 2757
Lakow, Ellen, 169
Lam, Tina, 1336
Lambris, John D., 1309, 1674
Lammie, Patrick J., 1381, 1386
Lampson, Lois A., 289, 2471
Lando, Zeev, 1205
Lane, H. Clifford, 165, 2663
Lang, Rosmarie, 2952
Langreth, Susan G., 1210
Laroche, Liliane, 2467
Lassila, Olli, 153
Latov, Norman, 2496
Lawn, Chieh-Yuan, 579, 586
Layton, Judith E., 2502
Lazarus, Robert, 2142
Le, Junming, 1231
Le, Phong T., 885
Lebel, B., 1937
Lebel, Bernard, 2343
LeBien, Tucker W., 1833
Le Bouteiller, Philippe P., 1432
Ledbetter, Jeffrey A., 1713
Lederman, Howard M., 45
Lederman, Michael M., 2484
Ledgley, Cynthia J., 1640
Lee, Jacob W. W., 45
Lee, Lucy F., 1003, 1007
Lefrancois, Leo, 394, 1408
Lehmeyer, Joyce E., 2763
Lei, Huan-Yao, 1274
Leibowitz, Julian L., 399
Leive, Loretta, 1867
Leizerovitz, R., 121
Lemanske, Robert F., 2837
Lemanske, Robert F., Jr., 1881
Lemonnier, François A., 1432
Leonard, Robert C. F., 1132
Lerner, Ethan, 2782
Leroux-Roels, Geert G., 1395
Leskowitz, Sidney, 579, 586
Lett-Brown, Michael A., 2104
Leung, Donald Y. M., 242, 524, 1678, 2002
LeVine, Mark J., 3484
Levi-Strauss, Matthieu, 777
Levy, Julia G., 1473
Levy, Robert B., 1506, 2514
Lewis, Robert A., 1885
Lewis, Verna M., 1924
Liang-Takasaki, Chieh-Ju, 1867
Lichtenstein, Lawrence M., 4, 2330, 2337

Stukart, Marijke J., 655
Stutman, Osias, 1749, 2075
Subbarao, Bondada, 2033
Subba Rao, Pillarisetti V., 341
Suemura, Masaki, 1056
Sugamura, Kazuo, 2942
Sugimoto, Masanobu, 2767
Sugimura, Kazuhisa, 1056
Sullivan, David A., 1330
Sullivan, Richard, 800
Sullivan, Timothy J., 1896
Sunday, Mary E., 1604, 2413
Sung, Chin K., 1
Sunshine, Geoffrey H., 546
Susskind, Brian M., 527
Sutherland, David C., 694
Suvunrungsi, Rachaneepas T., 1896
Suzan, Marie, 1476
Suzuki, Masao, 1189
Suzuki, Noriaki, 2552
Suzuki, Ryuji, 981, 988
Swanborg, Robert H., 732, 1503
Szejda, Pamela, 1910
Szewczuk, Myron R., 435
Szklut, P., 309

Tachibana, Katsumi, 2903
Tada, Nobuhiko, 2075
Tadokoro, Ichiro, 2920
Tagliabue, Aldo, 903
Taguchi, Masaaki, 2720
Takabayashi, Katsuhiko, 2552
Takahashi, Kazuaki, 2903
Takatsu, Kiyoshi, 2219
Takei, Fumio, 2794
Takeichi, Noritoshi, 501
Takenawa, Tadaomi, 2849
Talal, Norman, 2782
Talle, Mary Anne, 698
Tanaka, Kenichi, 463
Taniguchi, Masaru, 2552
Taniguchi, Noboru, 2737
Taramelli, Donatella, 1974
Tare, Nadine S., 791
Targan, Stephan R., 1252, 2671
Tartakovsky, Boris, 1017
Tax, Anne, 2368
Taylor, Christopher E., 19
Taylor, Ronald P., 2656
Teale, Judy M., 72
Tedder, Thomas F., 1668
Teichman, Faye, 1164
Teodorescu, Marius, 267
Terhorst, Cox, 2142
Terraneo, Loes, 2693
Teuscher, Cory, 317, 2675, 2683
Tevethia, Satvir S., 490
Tharp, Michael D., 1896
Theofilopoulos, Argyrios N., 2161
Theze, Jacques, 1521
Thoman, Marilyn L., 233, 1257
Thomas, David W., 637, 2542
Thomas, E. Donnall, 712
Thomas, Michael, 1910
Thomas, Wayne R., 2079, 2565
Thompson, Gary S., 1164
Thompson, Patricia A., 2708
Thorbecke, G. Jeanette, 15
Thorley-Lawson, David A., 2127
Tilden, Arabella B., 1171
Tishon, Antoinette, 912
Tite, John, 2083
Titus, Julie A., 130, 138, 619, 1152
Toffaletti, Dena L., 2982
Toh, B. H., 115
Toivanen, Paavo, 153, 2038
Tokuhisa, Takeshi, 2552
Tombes, Robert, 791
Tomioka, Hisao, 2552
Torii, Mitsuo, 1038
Torres, Barbara A., 2011
Toullet, F., 254
Towers, G. H. Neil, 1473
Trentham, David E., 2689
Trial, JoAnn, 565
Triglia, Dennis, 1627
Trinchieri, Giorgio, 1120, 2133, 2142
Trischmann, Thomas M., 1953
Troisi, Catherine L., 173
Truffa-Bachi, Paolo, 1103
Tsang, K. Roger, 1359
Tsang, Victor C. W., 1359, 1366
Tsoi, Mang-So, 712
Tsoukas, Constantine D., 169
Tsuchiya, Takehiko, 496
Tung, Kenneth S. K., 317, 2675, 2683
Tutschka, Peter J., 717

Uberti, Joseph, 2666
Uchida, Nobuyuki, 2767
Uchino, Haruto, 2720, 2942
Uede, Toshimitsu, 649, 878, 1802
Ugazio, Alberto G., 1129
Uhr, Jonathan W., 607, 614, 2502
Uksila, Jaakko, 153
Ulevitch, Richard J., 2757
Ul-Haq, Amin, 2156
Underdown, Brian J., 1176
Urban, James L., 2461
Urban, Joseph F., Jr., 350
Usuda, Sadakazu, 2903

Vadas, Mathew A., 795
Vahouny, George V., 791
Valet, Günter, 839
van der Gaag, Ruth, 722
van de Wijngaert, Frank P., 2343
Van Epps, Dennis E., 2316, 2727
van Leeuwen, Jolanda, 722
Van Rappard-Van Der Veen, Feikje, 2693
Varesio, Luigi, 1974
Vassalli, Pierre, 2225
Vaughan, John H., 162, 169
Vavrin, Zdenek, 261
Venuta, S., 2644
Verghese, Margrith W., 869
Vetter, Marsha L., 2121
Victor, Carol, 1819
Vik, Dennis, 1891
Viček, Jan, 1231
Villa, Luigi, 903
Vitetta, Ellen S., 607, 614, 2452, 2502
Vitiello, Antonella, 1129
Vogel, Stefanie N., 1210, 1774
Vose, Brent M., 228, 687, 768
Vukajlovich, Stanley W., 2804
Vydelingum, Soopayah, 2372

Wabuki-Bunoti, Melchizikek A. N., 2386
Wachter, Helmut, 1047
Wadee, Ahmed A., 2266, 2271
Wagener, Christoph, 2302, 2308
Wahl, Sharon M., 1226
Wähiin, Birgitta, 2831
Wainberg, Mark A., 2372
Wajda, Kim J., 665
Wakeland, Edward K., 1280
Waldeck, Nancy, 1189
Walford, Roy L., 993
Walker, C., 1770
Walker, William S., 1108
Wallick, Susan, 2871
Waltenbaugh, Carl, 506, 565, 1274
Wang, Sheng-Yuan, 2843
Ward, Frances E., 1863
Ward, Peter A., 1495
Warren, Keith, 845
Warren, Robert W., 1182
Warrington, Richard J., 237
Wat, Chi-Kit, 1473
Watanabe, Yoshihiko, 2720
Waters, Stanley J., 145
Watkins, Madeleine C., 785
Watson, Dougal B., 2442
Webster, R. O., 1997
Webster, Robert G., 1313
Wei, Wei-Zen, 1458
Weigle, William O., 233, 551, 1066, 1257, 2042, 2295, 2580
Weindruch, Richard, 993
Weinstock, Joel V., 418, 423
Weiss, Lola, 2452
Weiss, Mark A., 1790
Weissman, Irving L., 1097
Weitzen, Monica L., 2479
Wells, Martha A., 2908
Welte, Karl, 2635, 2644
Whelan, James P., 2471
Whisler, Ronald L., 248, 365, 665
White, Janice, 1033
Whiteside, Theresa L., 2149
Widmer, Michael B., 542
Wigzell, Hans, 2056
Wild, Gaynor C., 317, 2683
Wilkins, John A., 237
Williams, Ralph C., Jr., 1215
Williams, Terry W., 518
Williams, Thomas M., 2675
Wilner, George D., 637, 2542
Wilson, Britt C., 1359, 1366
Wilson, Curtis B., 2173
Winchester, Robert J., 145
Winfield, John B., 181
Wingard, John R., 327
Winkelstein, Alan, 2715
Wira, Charles R., 1330
Witte, Pamela L., 2282
Witter, Richard L., 1003
Wofsy, David, 1713
Wolff, Klaus, 1586
Wong, Henry L., 2557
Wood, D. D., 2191
Wood, Nancy, 1678, 2002
Wortzel, Richard D., 2461
Wright, Jennifer A., 2413
Wright, Katheryn, 1596
Wright, Susan C., 2479, 2960, 2965
Wyler, David J., 1371
Wysocki, Lawrence J., 515

Xue, Bin, 15

Yachie, Akihiro, 2737
Yaffe, L. J., 632
Yaffe, Lyn J., 2014, 2574
Yahara, Ichiro, 1759
Yamamoto, Hiroshi, 1038
Yamamura, Yuichi, 1056, 1241
Yamanouchi, Kazuya, 2814
Yamashita, Uki, 496
Yang, Y. H. Joy, 2308
Yasuda, Tomoyoshi, 2767
Yen-Lieberman, Belinda, 2561
Yokoyama, Kazushige, 1419
Yoneda, Kokichi, 2589
Yoshikawa, Yasuhiro, 2814
Yoshizaki, Kazuyuki, 1241
Yung, Yee-Pang, 2843
Yunis, Edmond J., 524

Zanetti, Maurizio, 2173
Zarling, Joyce M., 1556
Zeff, Richard A., 2809
Zeitz, Howard J., 2809
Zeleznik, Nancy J., 885
Zembala, Marek, 785
Zilberfarb, Vladimir, 1103
Zmuda, James, 362
Zöller, Margot, 2005

THE JOURNAL OF IMMUNOLOGY
Copyright © 1983 by The American Association of Immunologists
Vol. 130, No. 6
Printed in U.S.A.

SUBJECT INDEX TO VOLUME 130

N-Acetyl-*N'*-(5-sulfonic-1 naphthyl)ethylene diamine, cytotoxic T cells specific for antibody to, H-2L^d self products recognized by, 1506
Adenocarcinoma, semi-allogeneic H-2 antigen on, biochemical evidence, 471
Adenosine, defective suppressor T lymphocyte generation induced by, impaired immunoregulation in systemic lupus erythematosus, 1706
Adenosine deaminase, lymphoblast cell line deficient in, phenotypic reversion, 2866
Adenylate cyclase, hormonal activation in macrophage membranes, regulation by guanine nucleotides, 869
Adjuvant
  arthritis, attenuation by type II collagen, 2689
  derivatized guanine nucleosides, antibody responses and, 2580
Agglutinin, *Ricinus communis* and wheat germ, inhibition of OKT4 and OKT8 binding by, 1646
Aging
  cell cooperation and lymphocyte responsiveness to cytokines, effects on, 1754
  dietary restriction and, influence on natural killer cell activity, 993
  immunodeficiency, C8-derivatized guanine ribonucleosides and, 2042
  interleukin 2 endogenous production associated with, interferon and T lymphocyte activity, effects on, 1780
Alloantigen
  bone marrow cells stimulated by, cytotoxic cells generated from, 1084
  H-2S region controlled, 824
  Qa-1, 1293
  specific stimulation, cytolytic T lymphocyte proliferation to, 1545
  T cell, monoclonal antibodies to, 2798
Allodeterminant, Eβ and Eα, proliferative T cell clones recognizing, 1262
Allogeneic effect factor
  I-J-restricted, suppressor T cell activation by, 2250
  I-J-restricted self-reactive and alloreactive components of, allogeneic lymphocyte interaction analysis, 2241
  influence on B cell subpopulations, 632
Allograft
  rejection, lymphokine enhancing arginase activity during, 1937
  skin, enhanced histamine and histamine-producing cell-stimulating factor production, 2343
Alloimmunization, cytotoxic T lymphocyte precursor maturation and, 2056
Allotype
  idiotype and, Ia-binding alloactivated T cells, 1426
  T cell determinants, gene-encoded, 2920
Alveolar lining material, effect on macrophage receptors, 2589
Ambrosia elatior, pollen, antigens of, 727
Amines, primary, inhibition of B lymphocyte stimulation, 91
Anaphylatoxin
  C3a, generation from human C3 by mast cell tryptase, 1891
  immune response regulation mediated by, 1257
Antibody
  A/J, cross-reactive idiotype on, 1300
  anti-α, B cell activation, Fc-dependent inhibition of, 602
  anti-diphtheria toxoid, spectrotypes of, 818
  anti-idiotype, inhibition of B cell triggering by, 596
  anti-IgD, mixed lymphocyte reaction enhanced by, 2534
  anti-IgM, marrow lymphocyte production and, 644
  anti-immunoglobulin, effects on proliferation and differentiation, 2027
  anti-melanoma, secretion by Epstein Barr virus-transformed B cells, 2442
  anti-phospholipid, trypanosomiasis, 1390
  anti-receptor
    antigen-specific T cell hybridoma use in production, 1033
    Epstein Barr virus receptor extraction and, 1303
  H-Y-specific delayed-type hypersensitivity induced by, 1604
anti-T cell, suppressor inducer subset demonstration by, 157
assays, affinity requirements for, monoclonal antibodies and, 1809
auto-anti-idiotypic, inhibition of anti-tetanus toxoid antibody synthesis by, 1634
p-azophenylarsonate-binding, common heavy chain variable marker on, 2434
basement membrane, anti-tubular, 2173
cell-mediated activity dependent on, peripheral and intestinal lymphoid cells, 903
cell-mediated cytotoxicity dependent on
  activation, colony-stimulating factors and, 795
  effector cells, local activation, 1458
complement and, influenza neutralization, 1317
DNA/anti-DNA immune complexes, complement-mediated binding to neutrophils, 2656
igh-1-encoded IgG2a, T cell response to allelic determinants on, 1958
islet cell cytotoxicity mediated by, insulin-dependent diabetes and, 1189
leukocytic pyrogen, immunoglobulin-secreting cell generation by, 2708
monoclonal
  acute leukemia-associated antigen defined by, 2937
  against alliotypic determinants, 2920
  anti-gp70, passive transfer, 2363
  anti-herpes simplex virus, shared idiotype, 1943
  anti-Ia, cross-reactivity, 2786
  anti-Ia, inhibition of interleukin synthesis and T cell proliferation by, 1236
  anti-idiotope, suppressor T cell induction by, 2079
  anti-IgD, lymphoid cell surface phenotype, 15
  anti-I-J, inhibition of tumor growth by, 506
  anti-Leu-7, tissue distribution of natural killer cells, 2149
  anti-Leu-2 and anti-Leu-3, T lymphocyte blocking by, 2623
  anti-Lyb-2, B lymphocyte proliferation induction by, 2033
  anti-Lyt-1, anti-self-TNP and cytotoxic T lymphocytes, 1540
  anti-Lyt-2, cytolytic T lymphocyte precursor effects, 1552
  anti-Thy-1.2, autoimmunity treatment, 1713
  B2, B lymphocyte-asociated moiety defined by, 1985
  B73.1, reactivity with natural killer cells, 2133, 2142
  blocking of cytolytic T lymphocyte-mediated killing by, 2546
  carcinoembryonic antigen, avidin/biotin-based immunoassay with, 2302
  carcinoembryonic antigen, epitope specificities of, 2308
  characterization of small intestine mucosal lymphocytes by, 2615
  chlamydial antigen, 2899
  class II major histocompatibility complex, T and B cell differentiation, 2282
  cross-reactive, leukemia-suppression by, 2930
  effects on T lymphoblasts and interleukin 2, 51
  effects on viral growth, 2915
  epitopes of peptide 43-88 of myelin basic protein and, 2180
  functional subsets of monocytes defined by, 698
  granular lymphocytes identified by, suppressor cell function, 1171
  hematoporphyrin and, tumor photoimmunotherapy, 1473
  identification of primate lymphocytes, 1323
  immunoadsorption with, *Toxoplasma gondii* purification, 2407
  inhibition of adoptive transfer of encephalomyelitis, 1503
  inhibition of interleukin 2-driven proliferation, 749
  lectin and, interactions with mononuclear cells, 1646
  Marek's disease tumor associated antigen, 1007
  Marek's disease virus-specific, 1003
  monocyte-macrophage pattern definition, 145
  natural killer depletion, T lymphocyte generation and, 1556
  plasma cell-associated antigen identification by, 1132
  Schistosoma mansoni egg proteinase, 1
  serotherapy, hepatocarcinoma model for, 1451
  SFR3-DR5, 1863
  TA-1, recognition of leukocyte cell surface molecule by, 1833
  T cell alloantigen definition by, 2798
  T lymphocyte subpopulation analysis, cyclosporin A effects, 717
  T lymphocyte subsets with, characterization, 2075
  T lymphocyte surface antigens defined by, 2794
  viral glycoprotein, 1408
parasitemia control not mediated by, acute experimental Chagas' disease, 1953
phagocytosis dependent on, macrophage cell cycle influence on, 1108
regulation of production, idiotype-specific H-2-restricted T lymphocytes and, 1038
response
  guanine nucleosides as adjuvant for, 2580
  phosphocholine-specific, Lyb-5$^+$ and Lyb-5$^-$ B cell roles, 2574
  pneumococcal polysaccharide, T cell regulation, 19
responses, mucosal-associated lymphoid tissues during parasitic infection, 435
response specificity, *Schistosoma mansoni* microsomal antigens, 1366
responses to T cell independent antigens, nonspecific T cell factor requirement, 781
synthesis, inhibition of B lymphocyte stimulation by primary amines, 91
T cell lines and, cross-reactive idiotypic determinants on, 1814
Antigen
  absence of, antigen-specific B cell activation, 678
  acute leukemia-associated, definition by monoclonal antibody, 2937
  acute lymphoblastic leukemia, expression on melanoma cell lines, 2456
  Ambrosia elatior pollen, allergic response analysis, 727
  B2, Epstein Barr virus-converted lines, 1985
  B cells enriched by, activation of, 607, 614
  B cell triggering induced by, inhibition by anti-idiotype antibody, 596
  binding on basophils, 2330, 2337
  B lymphoblast, expression in Burkitt lymphoma lines, 2448
  carcinoembryonic
    monoclonal antibodies for, epitope specificities, 2308
    monoclonal antibody for, avidin/biotin-based immunoassay with, 2302
  cells bearing, immune capacity after bursectomy, 2038
  cells presenting, thymus, self-Ia recognition and, 2525
  cell surface
    B cell hybridomas with, 2027
    expression by T cell hybridoma, 565
    T cell characteristics, antibody response, 19
  chains binding, cell cycle-dependent expression, suppressor T cell hybridoma, 2552
  chlamydial, genus-specific, monoclonal antibodies to, 2876
  class I major histocompatibility complex
    intramolecular organization, 1419
    structural definition of immunodominant determinants, 1439
  cryptococcal, T suppressor cells induced by, 2876
  determinants, assignment to separated I-A^k chains, 2277

Antigen—*continued*
differentiation, leukemia cells, monoclonal antibody against, 2930
epidermal cells presenting, UV-B-induced impairment mechanism, 1586
expression on natural killer cells, 2947
fine specificity of recognition, T cell proliferative response to cytochrome *c*, 1527
gp52-cross-reactive, expression on B cell subset, 2368
H-2
expression by adenocarcinoma, 471
teratocarcinoma, splenic cell regulation of, 2969
T lymphocyte restriction, antibody production regulation and, 1038
helper T cells specific for, cross-reactive idiotypic determinants on, 1814
hepatitis B, genetic regulation of immune response to, 1395, 1401
hepatitis B e, immunochemical structure in serum, 2903
heterogeneity, melanoma, 1462
histocompatibility, pretreatment with, cytotoxic T lymphocyte helper cell activity and, 56
HLA, circulating maternal T and B cells in severe combined immunodeficiency, 2493
HLA-A2, structure, 1856
HLA-B27, immunochemical variants, 1288
HLA-DR5, SFR3-DR5 antibody specific for, 1863
H-Y, nonresponsiveness, defective presentation and, 655
Ia
alloactivated T cells binding to, 1426
biochemical characterization, 1268
clonal analysis of B and T cell responses to, 1262
expression on epidermal keratinocytes, 1536
mutant functional antigen-presenting cell lines, 2267
role in activation of T lymphocytes, 457
sharing between species, 2786
structural polymorphisms, wild and inbred mice, 1280
T cell proliferation and, 1236
T cell response to anti-Ia antibodies, 1958
Ia and H-2, biosynthesis and expression on a macrophage cell line, 449
Ia determinant, antigen-presenting capabilities of monocytes, 706
Ia region-associated membrane, expression on activated B cells, 626
identification of, interleukin 2 receptor distinction, 747
immunoglobulin production specific for, tetanus toxoid-specific T cell line induced, 1164
interaction with antibody, B73.1, lymphocyte membrane and, 2142
lipopolysaccharide, differential complement activation by *Salmonellae*, 1867
low dose, delayed-type hypersensitivity and, 1103
lymphocyte cell surface, LY-22.2, definition and genetics, 946
macrophage differentiation, expression and induction, 108
major histocompatibility, expression of cloned H-2D^d and H-L2^d genes, 465
major histocompatibility class II, extracellular domains of light chains, 808
major histocompatibility complex, humoral immunogenicity of subregions, 1017
melanoma-associated, high molecular weight, 1467
minor histocompatibility, helper cell-independent cytolytic T lymphocytes specific for, 542
mitogen activity induced by, schistosomiasis mansoni, 2891
monocyte-specific, expression in promyelocytic cell lines, 1120
OKM1, OKT3, and OKT8, quantitation of receptors on cells expressing, 1152
ontogeny of cells presenting, mixed lymphocyte reaction stimulation, thymus, 1592
parasite
immunosuppression by histamine, schistosomiasis, 1376
responses to, immunoregulation in filariasis, 1386
phagocyte differentiation, monocyte-macrophage expression patterns, 145
plasma cell, identification by monoclonal antibodies, 1132
Schistosoma mansoni microsomal, purification, 1359, 1366
self H-2^d, F_1 hybrid cytotoxic T lymphocyte specific for, 2429
simian virus 40 transplantation rejection, antigenic site demonstration, cytotoxic T lymphocyte clones, 490
Sm, isolated, molecular and antigenic nature, 2782
specificity, immunoglobulin idiotype and anti-anti-idiotype gene use and, 515
suppressor pathways specific and nonspecific for, mediation by T cell subpopulations, 1061
surface
hepatitis B peptide, epitopes associated with, 1947
proliferating T lymphocytes, 2794
tumor-associated, monoclonal antibodies reactive with Marek's disease, 1007
Tac, cyclosporin A effects, T cells and, 2737
T cell hybridoma specific for, anti-receptor antibody production, 1033
T cell independent, T cell factor requirement in antibody responses to, 781
T cell proliferation induced by, bone marrow-derived macrophage as accessory cells in, 661
thymic epithelial surface, severe cellular immunodeficiency and, 1182
thymic-independent, enhancement of B cell response to, 632
thymus-dependent and -independent, lupus and, 2161
tumor
immune response regulation to, 997
immunogenicity dependent on recognition of, 2005
tumor-specific, dissection with T cell clones, 2461
L-tyrosine-*p*-azophenyltrimethylammonium, suppressor T cells induced by, 2519
Anti-hapten, cytotoxic clones, analysis, 2046
Antisera, heterologous, antigen-specific T cell products, 2083
α1 Antitrypsin, effect on lymphocyte activation, 681
9-β-D-Arabinofuranosyladenine, immune enhancement by, 829
Arachidonate, metabolism, effects on leukocyte pyrogen/lymphocyte-activating factor/interleukin 1, 890
Arachidonic acid
metabolism in eosinophil, inhibition of lymphokine-directed migration, 1356
release in neutrophils, Ca^{2+} role, 2849
Arginase, activity enhancement, lymphokine and, allograft rejection, 1937
Arthritis, adjuvant, attenuation by type II collagen, 2689
Ascitic fluid, immune, effects on viral growth, 2915
Ataxia-telangiectasia, influenza virus-specific cytotoxic T lymphocytes in, defective production of, 2629
Autoantibody, B cells and, subsets, 162
Autoimmunity
bone marrow-associated Ly-6 determinant on T cell population, 1843
detection of cells proliferating to myelin basic protein, experimental autoimmune encephalomyelitis mediation, 1205
development delay, X-linked defect and, 1043
diabetes, low-dose streptozotocin-induced, genetic control, 1719
effector cells, encephalomyelitis and, 1503
gp70 immune complex, correlation to renal disease, 740
monoclonal antibody treatment, effects on lymphoproliferation and renal disease, 1713
thymic regulation of, 1200
Avidin, precipitating agent, solution phase immunoassay, 2302
p-Azobenenearsonate, poly-L-glutamic acid and, immune response to conjugate, 573
Azobenzenearsonate-*N*-acetyl-L-tyrosine, hapten-specific T cell response to, 579, 586
p-Azophenylarsonate
antibody families binding, common heavy chain variable marker on, 2434
IgE antibodies class specific for, presence of cross-reactive idiotype on, 1300

Bacteria, resistance mechanism, complement-mediated killing, 845
Basement membrane, anti-tubular antibody, characterization, 2173
Basophil
antigen binding on
antigen-specific IgE expression during antigen-induced desensitization, 2337
functional consequences, 2330
circulating, sensitization in serum-mediated cutaneous basophil hypersensitivity, 2104
dimeric and trimeric stimulation, comparison, 4
Behavior, immunosuppression conditioned by, antilymphocyte serum and, 2117
Behçet's disease, γ-interferon production and, 1683
Biotin, antibodies labeled with, avidin and, solution phase immunoassay, 2302
Blastogenesis
lymphocyte, seasonal rhythmicity, 2586
mitogen-induced, suppression, filariasis and, 1381
Blockade, IgA, immune lysis, 2882
Blood, peripheral B cells, heterohybridoma production and, 165
Blood-brain barrier, permeability, acute immune complex disease, 1695
Bone marrow
alloantigen-stimulated cells, cytotoxic cells generated from, 1084
chimera, radiation-induced, thymic antigen-presenting cells and, 2525
graft
cellular interactions and, 712
mutation and irradiation effects on natural resistance, 484
LY-6 determinant associated with autoimmunity and, 712
lymphocyte production, anti-IgM treatment and, 644
macrophage derived from, antigen-induced T cell proliferation and, 661
mast cells derived from, leukotriene B_4 generation, 1885
suppression, T cell-derived B cell growth and differentiation factors, 2502
transplantation, B cell leukemia therapy by, 2452
Bordetella pertussis, leukocytosis, promoting factor, effect on thymic lymphoepithelial cell association, 2767
Brugia pahangi
chronic infection, suppression of blastogenesis, 1381
responses to antigens, immunoregulation in filariasis, 1386
Bursectomy, immune capacity after, 2038

Ca^{2+}, phosphatidylinositol response and arachidonic acid release, response in neutrophils, T66
Cancer
disseminated, synergistic effects of immunotherapy and chemotherapy, 2987
therapy, 5-halo-6-phenyl pyrimidones and, 965
Carcinogenesis, immunologic suppression of, spontaneous hypertension with T cell depression, 501
Cell
accessory
monocyte-macrophage, differentiation-associated alteration, 2156
secondary cytotoxic response, virus-induced tumors, 1447
accessory or tumor, soluble factors, T cell colony dependence on, 2715
adherent peritoneal, natural killer activity suppression by, 1974
antigen-bearing, immune capacity after bursectomy, 2038
antigen-presenting
allogeneic lymphocyte interaction analysis, 2241
cytotoxic T cell sensitization inhibition, 2071
thymus, self-Ia recognition and, 2525
antigen-pulsed, T cell binding to, 2088
antigen-reactive, limiting dilution analysis, 29
autoimmune effector
encephalomyelitis induction without adjuvant, 732
experimental allergic encephalomyelitis, 1503
B
activated, Ia region-associated membrane antigen expression on, 626
activation, Fc-dependent inhibition of, 602

activation, interleukin 1 and, 2708
activation, T cell regulation of, 1061
activation suppression, 2022
allogeneic effect factor influence on subpopulations, 632
antigen-enriched, activation of, 607, 614
autoantibody-producing, 162
C3b receptor expression on, 1668
characterization of growth factor, 1241
clonal analysis of responses to Ia antigens, 1262
defect, isotype expression abnormalities and, 72
differentiation, soluble factors involved in, 2219
Epstein Barr virus-transformed, chlamydia antibody production, 2899
factor-induced antigen-specific responses, 678
growth and diffentiation factors, bone marrow suppression, 2502
growth factor secreted by T cell hybridoma, 777
hybridomas, cell surface antigens and, 2027
isotype commitment patterns in, 1640
leukemia, therapy by bone marrow transplantation, 2452
lineage, population changes in liver and spleen, neonate, 1616
Lyb-5$^+$ and Lyb$^-$, phosphocholine-specific antibody response, 2574
Lyb-5$^-$ subset, functional heterogeneity, 2014
ontogeny and distribution, 619
peripheral blood, heterohybridoma production and, 165
phospholipid synthesis and, 2568
plasmacytoma subset and, shared determinants, 2423
proliferation, immunoglobulin secretion and, 2597
proliferation stimulation, anti-Lyb 2, 2033
release of lymphokines acting on, T lymphocytes and, 2225
response inhibition by *Trypanosoma cruzi*, 908
subpopulations, T cell activation of, 67
subset, gp52—cross-reactive antigen expression, 2368
triggering inhibition by anti-idiotype antibody, 596
tumor, cytotoxic anti-idiotype effects on, 970
blast, acute leukemia-associated antigen expressed on, 2937
blood, ontogeny of concanavalin A and phytohemagglutinin responses, 2528
bone marrow, cytotoxic cells generated from, 1084
cooperation, effects of aging, 1754
cycle, antigen expression on activated B cells and, 626
effector
antibody-dependent cell-mediated, local activation, 1458
antibody-dependent lymphocyte-mediated cytotoxicity, 2R31
epidermal, UV-B-induced impairment of antigen-presenting capacity, 1586
Epstein Barr virus-infected, limiting dilution analysis, 1640
glomerular mesangial
proliferation suppression, macrophage supernatants and, 1790
thymocyte-activating factor derived from, 1796
helper
cytolytic T cell clones independent of, H-1-specific, 542
cytotoxic T lymphocyte, prevention of activity, 56
interactions
lymphocyte proliferation induction, 2093
marrow-grafted patients, 712
islet, antibody-mediated cytotoxicity, diabetes and, 1189
killer, selective defect against lymphomas, 1980
L, expression of cloned H-2D^d and H-L2^d genes after gene transfer, 463
Langerhans, enrichment, immunoadsorption. to *Staphylococcus aureus* cells, 2008
leukemia, suppression, cross-reactive monoclonal antibody, 2930
LMTK$^-$, transformation with purified HLA class I genes, 1432
lymphoid
cell surface phenotype, 15
neuraminidase and galactose oxidase-treated, T lymphocyte activation and, 2702
peripheral and intestinal, activity against *Salmonella typhimurium*, 903
peripheral blood, mixed epidermal cell-lymphocyte reaction, 2612
regulation of teratocarcinoma H-2 antigens, 2969
mast
biologic activity of granules, 1881
deficiency, delayed hypersensitivity and, 2565
granules, biologic activity, 2837
IgE-mediated histamine release from, 1896
leukotriene B$_4$ generation from, 1885
lung, activation, 2357
precursors, characterization, 2843
release of lymphokines acting on, T lymphocytes and, 2225
tryptase, kininogen inactivation by, 2352
minor lymphocyte stimulating locus, cytolytic T lymphocyte development and, 533
mononuclear
decrease in mitogen responsiveness, 694
lectin and monoclonal antibody interactions with, 1646
myeloid, acute leukemia-associated antigen expressed on, 2937
myelomonocytic, C3b receptor expression on, 1668
natural killer
activation by interleukin 2, 1970
activity, granular lymphocyte clone with, 524
activity inhibition by ultraviolet radiation, 2484
antigen expressed by, 2947
C3b receptor expression on, 1668
cytotoxicity mechanism, 2479
cytotoxicity mediated by, 2960, 2964
cytotoxic lymphocytes and, 2952
depletion with monoclonal antibodies, T lymphocyte generation, 1556
dietary restriction and aging effects on, 993
β-endorphin effects, 1658
function development, fetus, 153
heterogeneity, 1663
induction, 5-halo-6-phenyl pyrimidones and, 965
inhibition by granulocytes, 475
interleukin 2-induced proliferation of, 689
"lazy," Chediak-Higashi syndrome, 2671
lysis, phorbol ester-treated lymphocytes and, 2505
prostaglandin E-induced suppression of, cyclic AMP effects, 1350
reactivity of B73.1 antibody with, 2133, 2142
responder to interleukin 2, 981, 988
selective defect against lymphomas, 1980
soluble cytotoxic factor identification, 1252
suppression, β-estradiol effects, 974
suppression of activity by adherent cells, 1974
tissue distribution, 2149
neoplastic, Hodgkin's, mixed lymphocyte response stimulation by, 2666
OKT8-positive, OKT3-negative, immature subset identification in neonate, 1129
peripheral blood, antigen-induced mitogenic activity, schistosomiasis, 2891
plasma
antigen identification by monoclonal antibodies, 1132
IgG subclass expression by, 671
plasma cell, identification by monoclonal antibodies, 1132
semiallogeneic hybrids, augmented tumor immunity by, 2982
smooth muscle, C5a effects on, 1997
spleen, effects on antigen biosynthesis and expression, 449
Staphylococcus aureus, Langerhans cell enrichment and, 2008
stem, pluripotential hemopoietic, globulin as marker for, 1051
stimulator
requirements for allospecific T cell subsets, 546
spleen, anti-IgD-enhanced mixed lymphocyte reaction, 2534
suppressor
activating factor, 2266
activation, phospholipid binding to OKT8$^+$ lymphocytes, 2271
cytotoxic T cell sensitization inhibition, 2071
granular lymphocyte and, 1171
induction factor, 2720
photoallergic contact dermatitis induction and, 2099
T
abnormalities, mucocutaneous lymph node syndrome, 2002
activation of B cell subpopulations, major histocompatibility complex and, 67
activity, phenotypic differences, immune responses to insulins, 2062
alloantigen, monoclonal antibodies to, 2798
allospecific subsets, stimulator cell requirements for, 546
allotypic determinants, 2920
antigen-induced proliferation, marrow-derived macrophage and, 661
antigen-specific products, heterologous antisera to, 2083
anti-T antibody demonstration, 157
bone marrow-associated Ly-6 determinant on, 1843
capping of specific determinants, 38
cellular immune response to Epstein Barr virus and, 2127
clonal analysis of responses to Ia antigens, 1262
cloned with "co-helper" activity, 2209
colony, dependency on cell soluble factors, 2715
cytostatic, evidence for activity, 496
cytotoxic, helper factors for activation, 2214
cytotoxic, H-2L^d self products recognized by, 1506
cytotoxic, interleukin 2 effects on, 1780
cytotoxic, major histocompatibility complex restriction of, 63
cytotoxic, sensitization inhibition, 2071
cytotoxic, sequential action of lymphokines for induction, 2508
cytotoxic, suppression by spleen cells, 2200
cytotoxic, viral tract infection recovery and, 2908
cytotoxic hapten-specific, restriction by H-2 products, 2514
cytotoxic T lymphocyte development regulation and, 527
depression, immunologic suppression of carcinogenesis and, 501
differentiation, prothymocytes and, 121
distribution and homing of subsets, 1097
enhancement of immune responses mediated by, 1257
experimental autoimmune encephalomyelitis mediation, 1205
expression in promyelocytic cell lines, 1120
fibroblast-activating factor, 1226
growth, immunomodulatory role of interferon, 768
growth factor, viral inhibition, 2372
hapten-specific, restrictions, 573
hapten-specific response to azobenzenearsonate-*N*-acetyl-L-tyrosine, 579, 586
helper, antigen-specific, idiotypic determinants, 1814
helper, anti-influenza virus, 2379
helper, delayed-type hypersensitivity and, 1596
helper, heterogeneity of, 1749
helper and proliferating, terpolymer of L-glutamic acid-specific, 1521
hybridoma, B lymphocyte differentiation factor-producing, 1247
hybridoma binding to antigen-pulsed adherent cell monolayers, 2088
hybridoma, cell surface antigen expression by, 565
hybridoma, lymphokine production by, 1231
hybridoma secreting B cell growth factor, 777
idiotype-mediated resistance to hybridoma growth, 1478
idiotypes and allotypes on, 1426
IgG subclass expression, 671
I-J$^+$, allogeneic interaction, 2241
imunodeficiencies, interleukin 2-dependent natural killer lines in, 2635
interleukin 1-responsive Ly-1$^+$2$^-$ clones, 1743
lectin inhibition of monoclonal antibody binding to, 1646
limiting dilution of colonies, 1139
low dose-induced delayed-type hypersensitivity, mediation by, 1103
lymphotoxin and γ and α,β interferon production, 2231
mast cell precursor dissociation from, 2843
mitogens, spleen cell response to, skin allografts, 2343

Cell—*continued*
T—*continued*
mitogen-stimulated, 1241
mitogen-stimulated, cyclosporin A and Tac antigen expression of, 2737
myeloma IgE synthesis inhibition by, 1567
Nocardia asteroides killing mediated by, 2401
nonspecific factors in antibody responses, 781
phenotypes of subsets regulating colony growth, 665
profiles and function, diabetes and, 2168
proliferation, Ia antigen and, 1236
proliferation, phorbol myristate acetate and, 2261
proliferative response to cytochrome *c*, 1527
pteridines as marker for, 1047
reactivity, anti-H-2 I-A response and, 2067
receptor, self major histocompatibility complex gene products, 1512
regulation of B cell activation, 1061
replacement, guanine ribonucleosides and, 2042
replacing factors, B cell differentiation and, 2219
response inhibition by *Trypanosoma cruzi*, 908
response to anti-Ia antibodies, 1958
response to fibrinopeptide B, 2542
retrovirus-bearing, T cell lines specific for, 2942
secondary cytolytic responses, irradiation effects, 24
stimulation at low cell concentrations, 1759
subsets, differential locomotion, 1610
subsets, lymphocyte chemotactic factor produced by, T45
suppression, cyclosporin A effects, 1071
suppression by C3 fragments, 2605
suppressor, activation by I-J-restricted allogeneic effect factor, 2250
suppressor, cell-mediated lympholysis and, 2557
suppressor, cross-reactivity, 1498
suppressor, cryptococcal antigen-induced, 2876
suppressor, hybridomas, surface chains on, 2552
suppressor, induction by monoclonal anti-idiotope antibody, 2079
suppressor, sequential appearance, 2519
suppressor, subset characterization, 2075
surface markers, granular lymphocyte clone with, 524
tetanus toxoid-specific, 1164
thymus colony growth and characterization, 45
trinitrophenyl-specific, frequencies and regulation, 7
tumor-specific antigen dissection with, 2461
type III pneumococcal polysaccharide, antibody response, 19
Tα, IgA suppression by, 521
T acceptor, inhibitor of DNA synthesis produced by, 785
T and B
circulating maternal, severe combined immunodeficiency and, 2493
differentiation, monoclonal antibodies to class II molecules, 2282
T and mast, precursor evidence in gut intramucosal lymphocytes, 55
target, enhancement of lymphotoxin-induced killing, 518
thymic lymphoepithelial, *Bordetella pertussis* leukocytosis-promoting factor, effects on, 2767
thymic nurse, identification and localization, 2348
TMT mammary tumor, evidence for cytostatic T cell activity, 496
tumor, killing, macrophage priming activity of γ interferon, 2011
Cell cycle, antigen-binding and I-J-bearing chains dependent on, suppressor T cell hybridomas, 2552
Cell line
B lymphoblast, spontaneous occurrence and long-term culture, 2113
Ia mutant functional antigen-presenting, 2287
KE37, immunochemical properties of material produced by, 2295
lymphoblast, adenosine deaminase-deficient, phenotypic reversion, 2866
macrophage
antigen biosynthesis and expression on, 449
FcR-mediated endocytosis of model immune complexes by, 130, 138
procoagulant activity, lymphokine and lipopolysaccharide effects, 2750
macrophage-like, P388D$_1$, antibody-mediated infection with reovirus, 2915
melanoma, acute lymphoblastic leukemia antigen expression on, 2456
monocytic, growth and differentiation regulation by lymphokines, 2763
natural killer, interleukin 2-dependent, immunodeficiencies and, 2635
neuroblastoma, HLA-A, B, C and β_2-microglobulin paucity on, 2471
promyelocytic, leukocyte-conditioned medium, 1120
Raji, Epstein Barr virus receptor found on, 1303, 1309
T
cytotoxic, specificity for retrovirus-bearing cells, 2942
susceptibility to tumor promoters, 2732
tetanus toxoid-specific T cell, antigen-specific and polyclonal immunoglobulin production, 1164
T lymphoid, deoxyguanosine resistance acquisition by, 1622
Cell-lymphocyte reaction, epidermal, 2612
Cell sorter, fluorescence-activated, T cells separated by, severe combined immunodeficiency, 2493
Cell-stimulating factor, histamine-producing, enhanced production, skin allografts and, 2343
Cell surface, leukocyte, molecule recognition by monoclonal antibody TA-1, 1833
Cell wall, group A streptococcal, complement receptor capping on neutrophils induced by, 1674
Cerebrospinal fluid
blood and, barrier permeability, acute immune complex disease, 1695
mumps meningitis, HLA-restricted virus-specific cytotoxic T lymphocytes, 2187
Chagas' disease, acute experimental, non-antibody-mediated control of parasitemia in, 1953
Chain
heavy, *see* Heavy chain
light, *see* Light chain
structure, resistance of bound C4b to reduction, 2825
Chediak-Higashi syndrome, "lazy" natural killer cells of, 2671
Chemiluminescence
origin in zymosan-stimulated neutrophils, 2324
superoxide anion production and, lymphokine-induced cell differentiation, 2763
Chemoattractant, fibroblast, schistosomiasis, 1371
Chemotactic factor
neutrophil exposure to, respiratory burst enzyme potentiation, 2316
T lymphocyte, production by T cell subsets, 2727
Chemotherapy, immunotherapy and, synergistic effects in disseminated cancer, 2987
Chimera, bone marrow, radiation-induced, thymic antigen-presenting cells and, 2525
Chlamydia, monoclonal antibodies to, 2899
Choriomeningitis, lymphocytic, genetic control of C1q binding complexes in, 912
Chromosome, X-linked defect, delay in autoimmune disease expression, 1043
Circulation, C1q binding complexes in, genetic control of, 912
Cleavage
C5, surface-dependent modulation, 2821
CNBr, influenza hemagglutinin peptide, T lymphocyte stimulation, 2386
Collagen, type II, adjuvant arthritis attenuation by, 2689
Colony-stimulating factor
antibody-dependent cell-mediated cytotoxicity activation of, neutrophils and eosinophils, 795
binding to peritoneal exudate macrophages, lipopolysaccharide inhibition of, 2256
granulocyte-monocyte, synthesis and secretion by monocytes, 800
Colostrom, local production of IgG4 in, 1654
Complement
antibody and, influenza neutralization, 1317
antibody/dsDNA immune complex binding to neutrophils mediated by, 2656
C3
cleavage fragment, T cell proliferation inhibition by, 2605
cleavage products, prostaglandin release and, 874
effects on B lymphocyte C3b receptors, 1021
immunoglobulin with, generation in serum, 2775
isolation and identification, Japanese quail, 2814
C4, biosynthesis by macrophages, 834
C5, cleavage, surface-dependent modulation, 2821
C8, deficiency, decreased C5b67-inhibitor activity and, 2809
C3a, anaphylatoxin generation from, 1891
C3a 72-77, thromboxane release induction by, 1345
C5a
enhancement of immune responses, 1257
smooth muscle cells, effects on, 1997
C3b
inactivation in immune complexes, 1336
purified, stimulation of prostaglandin E and thromboxane synthesis by, 2861
receptor expression, 1668
C4b, cell-bound, reduction resistance, 2825
C5b-9-mediated killing, bacterial resistance to, 845
C3d, lymphocyte binding sites, 1309
depletion, effects on late phase reactions, 1881
differential activation, *Salmonellae* and, 1867
lysis, erythrocyte cell volume and osmotic properties after, 839
membrane-associated receptor CR1, functional properties, 1876
pathway activation, monoclonal IgE, 1341
receptor, capping on neutrophils, 1674
secretion, differences, macrophage maturation and, 102
Concanavalin A
ontogeny of blood cell responses, major histocompatibility complex compatible lines, 2528
T cell stimulation by, analysis of cellular events involved in, 1759
T lymphocyte stimulation, comparison, 2225
Conjugate, phosphocholine-protein, resistance to *Streptococcus pneumoniae* induced by, 2871
Convertase, C5, surface-dependent modulation of C5 cleavage by, 2821
Corticosteroid, thymosin peptides and lymphokines, effects on production, 791
Cross-reactivity, intraspecies, anti-Ia monoclonal antibodies, 2786
Cryptococcosis, cell-mediated immunity in, regulation, 2876
Cutaneous basophil hypersensitivity, passive transfer with immune serum, circulating basophil sensitization, 2104
Cyclic AMP, natural killer activity, mediation of prostaglandin E-induced suppression, 1350
Cyclophosphamide
fractional dosage, red blood cell-delayed-type hypersensitivity and, 1600
immune lymphocytes and, combination therapy, 2511
sublethal dose, cytotoxic T lymphocyte precursor regeneration after, 1077
T acceptor cells sensitive to, inhibition of cell proliferation liberation, 785
Cyclosporin A
effect on lymphocyte responses, 717
effects on T cell suppression, 1071
Tac antigen expression on mitogen-stimulated T cells and, 2737
Cytochalasin B, effects, granulocyte activation by endotoxin, 863
Cytochrome *c*, T cell proliferative response to, fine specificity of antigen recognition in, 1527
Cytokine, lymphocyte responsiveness to, effects of aging, 1754
Cytolysis
natural killer cell-mediated, phorbol ester-treated lymphocytes and, 2505
T lymphocyte, reversible, phorbol ester mediation by, 2499
Cytometry
flow
complement lysis measured by, 839
studies of polymorphonuclear leukocyte oxidative bursts, 1910
Cytotoxicity
absence of, cyclosporin A effects on T cell sup-

pression, 1071
antibody-dependent cell-mediated
effector cells, local activation, 1458
neutrophils and eosinophils, 795
antibody-dependent lymphocyte-mediated, cellular basis of regulation by C3 fragments, 2831
antibody-mediated islet cell cytotoxicity, insulin-dependent diabetes and, 1189
monocyte, regulation, 1220
natural, enhancement by β-endorphin, 1658
natural killer, mechanism of, 2479
natural killer cell-mediated, mechanism, 2960, 2964
neutrophil-mediated, chemotactic enhancement, 850
proliferative frequency and, lectin effects, 687

Degranulation, neutrophil, histamine modulation, 1902
Deoxyguanosine, resistance acquisition, 12-O-tetradecanoylphorbol-13-acetate-induced T lymphoid lines, 1622
Dermatitis
atopic, cellular basis of defective cell-mediated lympholysis in, 1678
photoallergic contact, induction, suppressor cells and, 2099
Desensitization, antigen-induced, continued antigen-specific IgE expression during, 2337
Determinant
alloantigenic, localization to H-2 K^b glycoprotein regions, 1419
allotypic, T cell, 2920
antigenic, assignment to separated I-A^k chains, 2277
cross-reactive idiotypic, antibodies and T cell clones, 1814
hepatitis B surface antigen, immune response characteristics, 1395
Igh-1^a allotypic, localization with myeloma variant immunoglobulins, 1967
immunodominant, structural definition, 1439
Ly-6, bone marrow-associated, expression on T cell population, 1843
major histocompatibility complex, T cell activation, pteridine and, 1047
polymorphic Ia, monoclonal antibody cross-reactivity against, 2786
recognition, anti-herpes simplex virus monoclonal antibodies, 1943
sequential disease-inducing, aspermatoic polypeptide with, orchitis, 2683
T cell specific, capping kinetics, 38
target for F_1 hybrid anti-parental *H-2*^{d} lympholysis, self H-2^d antigens and, 2429
V_H, B and plasma cells and plasmacytoma subset expression, 2423
Dexamethasone, cellular protein synthetic responses, thymocyte subpopulations, 115
Diabetes
autoimmune, low-dose streptozotocin-induced, genetic control, 1719
insulin-dependent, immune islet killing mechanisms associated with, 1189
mellitus, T lymphopenia and pancreatic infiltration in, 1732
spontaneous, peripheral T lymphocyte immunodeficiencies in, 1723
T cell profiles and function, 2168
thymic dysfunction and, 1195
Diet, restriction, influence on natural killer cell activity, 993
Differentiation, alteration associated with, accessory cell function, 2156
Diphtheria, toxoid antibodies against, spectrotypes of, 818
DNA, synthesis inhibitor, production by T acceptor cells, 785

Effector mechanism, evidence for cytostatic T lymphocyte activity in, syngeneic TMT mammary tumor cells, 496
Encephalitogenicity, myelin basic protein and, 2183
Encephalomyelitis
experimental allergic
induction without adjuvant, 732
relapsing, myelin basic protein-induced, 1024
transfer inhibition, 1503
experimental autoimmune, mediation by T cell lines, 1205
Endocytosis, FcR-mediated, small oligomers of IgG, 130
β-Endorphin, enhancement of natural cytotoxicity, 1658
Endotoxin
bacterial, granulocyte-monocyte colony-stimulating activity response to, 800
granulocyte activation by, 857, 863
splenocytes unresponsive to, lipopolysaccharide responsiveness in, 2804
T lymphocyte proliferation induced by, 1774
Environment, stimulatory, B cell defect *vs.*, isotype expression abnormalities, 72
Eosinophil
antibody-dependent cell-mediated cytotoxicity of, activation by colony-stimulating factors, 795
lymphokine-directed migration of, inhibition by nonsteroid anti-inflammatory drugs, 1356
Epinephrine, administration, decrease in mitogen responsiveness of mononuclear cells after, 694
Epithelium, abnormal thymic, severe cellular immunodeficiency and, 1182
Epitope
peptide 43-88, myelin basic protein, 2180
specificities, monoclonal anti-carcinoembryonic antigen antibodies, 2308
synthetic hepatitis B surface antigen peptide and, 1947
Erythrocyte
cell volume and osmotic properties of, complement lysis and, 839
delayed-type hypersensitivity and, fractional cyclophosphamide dosage and, 1600
requirement inactivation of C3b, immune complexes, 1336
Erythroleukemia, K562, heterogeneity of natural killer cells, 1663
β-Estradiol, tumor metastasis and natural killer cell, effects on, 974

Fc
B cell activation inhibition dependent on, 602
dependence of macrophage accumulation, experimental glomerulonephritis, 735
intact region, opsonic IgG for type 6 streptococci, 896
macrophage phagocytosis dependent on, enhancement by resident thymocytes, 2195
receptor
analysis on peripheral blood leukocytes, 1152
blocking by monoclonal antibody B73.1, 2133, 2142
macrophage cell cycle influence on, 1108
macrophage, interferon enhancement of, 1210
polyclonal B cell activation suppression mediated by, 2022
Fcγ, soluble binding material, immunochemical properties, 2295
FcR, endocytosis mediation, model immune complexes, 130, 138
Fibrinopeptide B
T cell responses to, 2542
T lymphocyte responses to, functional differentiation in genetic control of, 637
Fibroblast
C3H, SV40 transformed, gene defect of, 2418
gingival, C1Q receptors on, 1871
HSV-1-infected, heterogeneity of natural killer cells, 1663
modulation of growth by lymphokine, 1226
stimulation, schistosomiasis, 1371
Ficoll, haptenated, helper activity with, 579, 586
Filariasis
experimental
immunoregulation, responses to antigens, 1366
nonspecific immunoregulation in, 1381
Fine-specificity, 4-hydroxy-3-nitrophenyl acetyl contact sensitivity, 97
Formyl peptide, chemotactic receptor modulation on neutrophil, prostaglandin E_1 and, 1495

Galactose oxidase, neuraminidase and, lymphoid cells treated with, T lymphocyte activation, 2702
Gammapathy, monoclonal, Sjogren's syndrome and, 2663
Gammopathy, IgA monoclonal, polymeric IgA estimation in serum, 1176

Gene
class II, variations in wild and inbred mice, 1280
DNA-mediated transfer, expression of H-2D^d and H-$L2^d$ genes, 465
H-2
defect, SV40 transformed C3H fibroblasts, 2418
transferred, anti-hapten cytotoxic T cell restriction and, 2514
Igh-1 allotype locus, Ia-binding alloactivated T cells, 1426
I-J products, regulation of immune responses by, 1274
immunoglobulin heavy chain locus, T cell allotypic determinants encoded by, 2920
Ir
control of immune responses to insulins, 2062
control of Sendai virus-specific cytotoxic T lymphocyte, 1090
regulation of T cell-dependent activation of B cell subpopulations, 67
I region, self-recognition, thymus antigen-presenting cells and, 2525
low-dose streptozotocin-induced autoimmune diabetes, control of, 1719
major histocompatibility complex-linked Ir, control of T cell responses, 1521
purified HLA class I, transformation of LMTK$^-$ cells with, 1426
Qa-1 and *H-2K*, expression of Qa-1 molecules by, 1293
Rfv-3, monoclonal anti-gp70 antibodies and, Friend virus-induced leukemia, 2363
self major histocompatibility complex products, diversity of T cell receptors specific for, 1512
variable region, use by immunoglobulin idiotype and anti-anti-idiotype, 515
Gene product, I-A, anti-H-2 response, heterogeneity, 2067
Gingiva, fibroblasts, C1Q receptors on, 1871
Globulin, macromolecular insoluble coid, marker for pluripotential hemopoietic stem cells, 1051
Glomerulonephritis, experimental, Fc-dependent macrophage accumulation, 735
L-Glutamic acid, terpolymer of, proliferating and helper T cells specific for, 1521
L-Glutamic^{60}-L-alanine^{30}-L-tyrosine response, *H-21* region requirements for, antigen-induced T cell proliferation and, 661
Glycoprotein
gp52, antigen cross-reactive with, 2368
herpes simplex virus, delayed hypersensitivity and protective immunity induced by, 1413
H-2 K^b, intramolecular organization of class I antigens, 1419
myelin-associated, reaction with M-proteins, neuropathy and, 2496
Thy-1, expression and glycosylation patterns of, 1837
viral, monoclonal antibodies directed to, 1408
Glycosaminoglycan, thymus, biosynthesis, 1848
Glycosylation
expression and, Thy-1 glycoprotein, 1837
factor enhancing, physicochemical properties and cell sources, 1802
inhibition factor, identification as lipomodulin fragment, 878
Graft, marrow, mutation and irradiation effects on natural resistance, 484
Grafting, Ia antigen expression on epidermal keratinocytes, 1536
Graft-*vs.*-host disease
cytotoxic T lymphocyte suppression and, analysis of T lymphocyte markers during, 1561
impairment of cell-mediated lympholysis and, marrow grafts, 712
lupus-like, standardization, optimal doses of spleen cells, 2693
Granule, mast cell, biologic activity, 1881
Granulocyte
activation by endotoxin, 857, 863
monocyte and, colony-stimulating activity, synthesis and secretion, 800
peripheral blood, natural killer cell activity regulation by, 475
selenium-deficient, altered oxidative metabolism in, 2856
Granuloma
fibroblast chemoattractant elaboration, schistosomiasis, 1371
schistosome, macrophages, immune response induction by, 2413

Growth factor
B cell, bone marrow suppression and, 2502
T cell
receptor, cyclosporin A and Tac antigen expression, 2737
viral inhibition, 2372
T lymphocyte activation, requirements for, 2702
Guanine
derivatized nucleosides, immunopotentiation by, 2580
regulation of hormonal activation of adenylate cyclase, macrophage membranes, 869
ribonucleosides, C8-derivatized, T cell-replacing activity of, 2042

H-2, T cell hybridoma restrictions, binding to antigen-pulsed adherent cell monolayers, 2088
Haplotype
nonresponder
hepatitis B surface antigen, nonresponsiveness, 1401
T cells restricted to, 573
Hapten
altered self
cytolytic T lymphocyte development and, 533
cytolytic T lymphocyte response to, suppression, 2557
cytotoxic T cells specific for, restriction by transferred H-2 products, 2514
initiator, delayed-type hypersensitivity, prevention of tolerance, 2561
liberation of cell proliferation inhibitor driven by, 785
phenyltrimethylamino, hapten-specific responses to, 2519
specific T lymphocyte precursors, tolerance induction, 78
sulfhydryl reagents, lympholytic responses against cells modified with, 1506
T cells specific for
response to azobenzenearsonate-*N*-acetyl-L-tyrosine, 579, 586
restrictions, 573
Heavy chain
allotype-defined mRNA for, 442
anti-oxalozone, mRNA sequences, 937
genes linked to, T cell allotypic determinants encoded by, 2920
β_2-microglobulin associated with, conformation modification, 1432
variable region marker, α1-3 dextran and *p*-azophenylarsonate-binding proteins, 2434
Hemagglutinin
influenza virus, T lymphocyte stimulation, 2386
influenza virus A/PR/8/34, helper T cell for, 2379
Hematoporphyrin, monoclonal antibody and, tumor photoimmunotherapy, 1473
Hemocyanin, keyhole limpet, *in vitro* immunization to, 29
Hemolysis, analysis, resistance of bound C4b to reduction, 2825
Hemolytic plaque assay, complement secretion detection, macrophage maturation, 102
Hepatitis B
e antigen, immunochemical structure in serum, 2903
surface antigen
genetic regulation of immune response to, 1395, 1401
synthetic peptide, epitopes associated with, 1947
Hepatocarcinoma, monoclonal antibody serotherapy model, localization, 1451
Heredity, C8 complement deficiency, decreased C5b67-inhibitor activity and, 2809
Herpes labialis, γ interferon and, 2397
Herpesvirus, transient paralysis induced by, prevention, humoral immunity suppression and, 2000
Heterogeneity
antigenic, melanoma, 1462
molecular aggregates with, lipopolysaccharide conversion to, 2804
natural killer cells, comparison of effectors, 1663
T helper cell, limiting dilution analysis, 1749
Heterohybridoma, mouse-human, optimal conditions for production, 165
Histamine
antigen-specific, release, cutaneous basophil hypersensitivity and, 2104
enhanced production, skin allografts and, 2343
IgE-mediated release from mast cells, 1896
IgE-mediated release from mast cells, triggering events, 2357
immunosuppression by, schistosomiasis, 1376
modulation of neutrophils, oxidative metabolism, locomotion, degranulation, and membrane changes, 1902
Histocompatibility, antigens, pretreatment with, cytotoxic T lymphocyte helper cell activity and, 56
Histocompatibility complex
major
antigen expression induction on macrophage cell line, 449
antigen expression of H-2D^d and H-L2^d genes, 465
B cell response enhancement restrictions, 632
class I antigens, determinant structure, 1439
class I antigens, humoral immunogenicity, 1017
class II antigens, 808
clonal analysis of restriction, 1527
cytotoxic T cell restriction, 63
gene products, T cell receptors specific for, 1512
intra- and extra-thymic cytotoxic T lymphocytes, 1027
intramolecular organization of class I H-2 antigens, 1419
Ir gene control of T cell responses, 1521
mixed lymphocyte responses, Ia molecules and, 457
monoclonal antibodies to, 2282
ontogeny of concanavalin A and phytohemagglutinin blood cell responses, 2528
restriction of cytotoxic T lymphocyte precursors, 1077
restrictions, 573
role in T cell activation of B cell subpopulations, 67
T cell activation, pteridine and, 1047
teratocarcinoma antigens, splenic cell regulation of, 2969
minor, complexity of *H-3* region, 2926
HLA
A, B, and C, paucity on neuroblastoma cell lines, 2471
class I genes, transformation of LMTK$^-$ cells with, 1432
restrictions, cerebrospinal fluid in mumps meningitis, 2187
HLA-DR, synthesis and expression, increases, interferon-γ and, 1492
Hodgkin's disease, neoplastic cells from, mixed lymphocyte response stimulated by, 2666
Hormone
activation of adenylate cyclase, regulation by guanine nucleotides, 869
adrenocorticotropic, steroidogenesis induced by, suppression by macrophage product, 2757
Hybrid, semiallogeneic cell, augmented tumor immunity by, 2982
Hybridoma
anti-oxazolone, oxazolone idiotype structure and, 937
B, IgE production in, inhibition of, 1056
B cell, B cell surface antigens and, 2027
growth, idiotype-mediated resistance to, 1478
plasma cell, identification by monoclonal antibodies, 1132
rabbit-mouse, allotype-defined mRNA from, 442
suppressor T cell
cell surface antigen expression by, 565
surface chains on, 2552
T, IgE class-specific suppressor factor from, 1056
T cell
binding to antigen-pulsed adherent cell monolayers, 2088
expression in promyelocytic cell lines, 1120
I region restricted antigen-specific, antibody production and, 1033
lymphokine production by, 1231
production of B lymphocyte differentiation factor by, 1247
secretion of B cell growth factor by, 777
Hydrocortisone acetate, T lymphocyte precursor recovery and, kinetic analysis, 33
Hydrogen peroxide, myeloperoxidase and, IgG aggregation, 1918
4-Hydroxy-3-nitrophenyl acetyl, contact sensitivity to, fine-specificity, 97
Hypersensitivity
cutaneous basophil, circulating basophil sensitization in, 2104
delayed
interferon and, Newcastle disease virus, 2392
mast cell deficiency and, 2565
delayed-type
anti-receptor antibody-induced H-Y-specific, 1604
haptenic initiator, prevention of tolerance, 2561
induction, helper T cells and, 1596
low dose-induced, 1103
red blood cell and, fractional cyclophosphamide effects, 1600
type-specific delayed, glycoprotein-induced, 1413
Hypertension, spontaneous, T cell depression and, immunologic suppression of carcinogenesis, 501

Idiotope, expression, suppressor T cell induction by monoclonal anti-idiotope antibody, 2079
Idiotype
allotype and, Ia-binding alloactivated T cells, 1426
B lymphocytes and, association with immunoglobulins, 1819
chains bearing, composition of GT-specific suppressor factor, 1274
cross-reactive determinants, antibodies and T cell clones, 1814
immunoglobulin
gene use and antigen specificity, 515
immunization with, effects on leukemia and tumors, 970
interactions with anti-idiotypes, tetanus toxoid and, 1634
intrastrain cross-reactive, presence on IgE antibodies, 1300
M-proteins, reaction with myelin-associated glycoprotein, neuropathy and, 2496
oxazolone, structure, anti-oxazolone hybridomas and, 937
resistance to hybridoma growth mediated by, 1478
shared, monoclonal anti-herpes simplex virus antibodies, 1943
shifts, neonatal tolerance to phosphorylcholine and, 590
specific anti-receptor antibodies, production, 1033
suppression, mechanisms of, 596
T lymphocytes specific for, antibody production regulation, 1038
Immune alteration, tumor rejection by, allogeneic transplants, 951
Immune complex
acute disease, blood-cerebrospinal fluid barrier permeability during, 1695
C3b inactivation, red blood cell requirement in, 1336
FcR-mediated endocytosis of, 130, 138
gp70, lupus and renal disease correlation, 740
IgA, clearance kinetics, 1826
polyclonal activation of B lymphocytes by, 1066
soluble antibody/dsDNA, complement-mediated binding to neutrophils, 2656
virus-induced formation, genetics of, 912
Immune response, *see* Response, immune
Immune serum, cutaneous basophil hypersensitivity transfer with, circulating basophil sensitization, 2104
Immunity
cell-mediated
macrophage procoagulant activity and, 2743
regulation in cryptococcosis, 2876
humoral, suppression, herpesvirus paralysis prevention and, 2000
influenza-specific, maternal-infant transfer, 932
protective, glycoprotein-induced, 1413
syngeneic tumor-specific, augmentation by semiallogeneic cell hybrids, 2982
Immunization
idiotypic immunoglobulin, effects on leukemia and tumors, 970
IgG4-restricted response, results, 722
Immunoadsorption, monoclonal antibody, *Toxoplasma gondii* protein purification, 2407
Immunoassay, avidin/biotin-based, monoclonal carcinoembryonic antigen antibodies and, 2302
Immunochemistry, variants of HLA-B27, 1288
Immunodeficiency
aging, C8-derivatized guanine ribonucleosides and, 2042
peripheral T lymphocyte, diabetes and, identification, 1723
primary, interleukin 2 in, 2644
severe cellular, abnormal thymic epithelium in, 1182

severe combined, circulating maternal T and B cells in, 2493
T cell, interleukin 2-dependent natural killer lines in, 2635
Immunogenicity
humoral, major histocompatibility complex subregions, 1017
spontaneous tumors, recognition of processed tumor antigens, 2005
Immunoglobulin
antigen-specific and polyclonal, tetanus toxoid-specific T cell line, 1164
anti-IgD, lymphoid cell surface phenotype, 15
anti-IgM, marrow lymphocyte production and, 544
Fab fragment, monoclonal, affinity constant, 1313
generation of cells secreting, antibody against leukocytic pyrogen, B cell activation and, 2708
H and L chains, allotype-defined for, 442
histamine release mediated by, mast cell activation, 2357
idiotype and anti-anti-idiotype, structure, 515
idiotypes on B lymphocytes and, 1819
idiotypic, immunization with, protection against leukemia, 970
IgA
blockade of immune lysis, 2882
estimation in serum, 1176
isotype-specific suppression of, 521
monomeric or dimeric, immune complex kinetics, 1826
IgE
antibodies, cross-reactive idiotype on, 1300
antigen-specific, expression during antigen-induced desensitization, 2337
binding factor, 649
biological modulation of binding factors, 878
factor binding to, activity modulation, 1802
histamine release mediated by, 1896
monoclonal, complement pathway activation by, 1341
myeloma, inhibition of synthesis, 1567
production inhibition by IgE class-specific suppressor factor, 1056
receptor complexes, isolation from macrophages, 1489
responses, ragweed-allergic patients, 727
IgG
aggregation by myeloperoxidase and hydrogen peroxide, 1918
analysis of Fc receptors on leukocytes, 1152
endocytosis of self-aggregating oligomers of, 138
humoral immunogenicity of major histocompatibility complex, 1017
internalization of oligomers of, 130
opsonic activity requirements, 896
polyclonal B cell activation suppression, 2022
spectrotypes of anti-diphtheria toxoid antibodies, 818
subclass expression by B lymphocytes and plasma cells, 671
IgG4
local production in colostrum, 1654
serologic effects, 722
IgG2a, Igh-1-encoded antibodies, T cell response, 1958
IgM, anti-herpes simplex virus monoclonal antibodies, 1943
IgM, IgG, and IgA, immunoregulation during parasitic infection, 435
IgM and IgD, B cell, 619
α-interferon effects on production, mononuclear leukocytes, 1215
low molecular weight C3-bearing, generation in serum, 2775
myeloma variant, Igh-1^a allotypic determinant localization with, 1967
secretion
autologous mixed lymphocyte reaction, 1146
B cell proliferation and, 2597
tumor promoter-induced suppression, 1159
surface, immune capacity after bursectomy, 2038
synthesis, C3 effects on, 1021
Immunopathology, experimental allergic orchitis, 2675
Immunopotentiation, derivatized guanine nucleosides, adjuvant for antibody responses, 2580
Immunoregulation
impaired, systemic lupus erythematosus and, 1706
leukocytic pyrogen/lymphocyte-activating factor/interleukin 1, effects of arachidonic metabolism in, 890
nonspecific, experimental filariasis, 1381, 1386
parasitic infection and, 435
T cell abnormalities, mucocutaneous lymph node syndrome, 2002
thymocytes and, lipomodulin, 1930
Immunosuppression
behaviorally conditioned, antilymphocyte serum and, 2117
histamine, schistosomiasis, 1376
lipomodulin and, 1930
parasite-specific, experimental African trypanosomiasis, 2896
Immunotherapy, chemotherapy and, synergistic effects, disseminated cancer, 2987
Infant, transfer from mother, influenza-specific immunity, 932
Infection
reovirus, antibody-mediated, P388D$_1$ cell line, 2915
viral tract, recovery specificity by cytotoxic T cells, 2908
Inflammation
C-reactive protein changes induced by, plasma lipoproteins and, 1736
response to, serum amyloid P-component, 885
Influenza
immunity specific for, maternal-infant transfer of, 932
neutralization, antibody and complement mechanisms, 1317
virus A/PR/8/34, helper T cell for hemagglutinin of, 2379
virus neuraminidase, interaction with Fab fragment, equilibrium constant, 1313
Inhibitor, C5b67, decreased activity, C8 complement deficiency and, 2809
Insulin
diabetes dependent on, immune islet killing mechanisms associated with, 1189
imune responses to, *Ir* gene control of, 2062
Interferon
α and α/β, protein A-induced production, 773
delayed hypersensitivity and, Newcastle disease virus, 2392
immune
γ, interleukin 2-mediated production, 1784
secretion, interleukin 2 effects on, 1780
immunomodulatory role, large granular lymphocyte and T cell growth, 768
induction, 5-halo-6-phenyl pyrimidones and, 965
low responsiveness to inducers, natural killer and killer cell defect, lymphomas and, 1980
lymphokines and, regulation of monocyte cytotoxicity, 1220
natural killer activity augmentation mediated by, suppression by peritoneal cells, 1974
natural killer cell activation by, production of natural killer cytotoxic factors and, T88
natural killer cell lysis susceptibility induced by, natural killer cytotoxic factor release defect, T87
production, T lymphocyte comparison, 2225
stimulation, IgE-binding factor formation and, 649
synergism between lymphotoxin and, enhancement of target cell killing, 518
thoracic duct lymphocyte output, effects on, 2236
α Interferon, effects on immunoglobulin production, 1215
α,β Interferon, production, T cell lines and clones, 2231
β Interferon, enhancement of macrophage Fc receptors, 1210
γ Interferon
anticellular and protein-inducing activities of, 1019
herpes labilis and, 2397
interleukin 2-induced production, natural killer cells, 988
interleukin 2-mediated production, T cells and subsets, 1784
production, T cell lines and clones, 2231
recombinant, macrophage priming activity, 2011
recombinant, HLA-DR increase and, 1492
spontaneous production, Behçet's disease and, 1683
Interleukin
assays, phorbol myristate acetate effects on, 1764
inhibition of synthesis, monoclonal anti-Ia antibody, 1236
Interleukin 1
adjuvanticity *in vivo*, 2191
B cell activation and, 2708
defective production, systemic lupus erythematosus and, 2651
immunoregulatory function of, effects of arachidonate metabolism in, 890
Ly-1$^+$2$^-$ T cell clones responsive to, disparate functional properties, 1743
Interleukin 2
age-associated endogenous production, interferon and T cell activity, 1780
defective production, systemic lupus erythematosus and, 2651
differentiation factor distinct from, cytotoxic T lymphocyte generation, 763
helper factors distinct from, cytolytic T lymphocyte generation and, 756
immune interferon production mediated by, T cell subsets, 1784
inhibitor neutralization, cytolytic T lymphocyte development and, 533
in vivo, 2203
large granular lymphocyte and T cell growth, interferon effects, 768
marrow grafts and, impairment of cell-mediated lympholysis, 712
monosaccharides and, T cell cytotoxicity suppression, reversal by, 2200
natural killer cell activation by, 1970
natural killer cell lines dependent on, T cell immunodeficiencies and, 2635
natural killer cell proliferation induced by, 687
natural killer cells as responder to, proliferative response and establishment of cloned cells, 981, 988
primary immunodeficiency diseases, immunologic effects of, 2644
proliferative responses driven by, inhibition by monoclonal antibody, 747
prostaglandin E_2-induced inhibition, lymphokine regulation of activated (G_1) lymphocytes, 1770
receptor function inhibition, monoclonal antibody, 51
release, T lymphocyte comparison, 2225
spleen cell-derived helper factors and, cytotoxic T cell activation, 2214
T helper cell heterogeneity, limiting dilution analysis, 1749
Interleukin 3, T helper cell heterogeneity, limiting dilution analysis, 1749
Intestine, small, mucosal lymphocytes of, 2615
Ionophore
Ca^{2+} A23187, neutrophils stimulated by, 2849
leukotriene B_4 generation induced by, bone marrow-derived mast cells, 1885
Irradiation, *see* Radiation
Isotype
abnormalities in expression, environment *vs.* B cell defect, 72
commitment patterns in B cells, Epstein Barr virus-infected cells, 1640
specific suppression of IgA, 521

Kallikrein, cleavage fragment, T cell proliferation inhibition by, 2605
Keratinocyte, epidermal, expression of Ia antigen on, 1536
Keyhole limpet hemocyanin, *in vitro* immunization to, 29
Kidney
disease
autoimmunity treatment with monoclonal antibody, 1713
retroviral gp70 immune complex, correlation to, 740
Kininogen, high molecular weight, inactivation by mast cell tryptase, 2352

Lactate dehydrogenase B, IgG2a myeloma protein and, cross-reactivity of suppressor T cells specific for, 1498
Lectin, monoclonal antibodies and, interactions with mononuclear cells, 1646
Letters to the Editor, 1012, 1990
Leukemia
acute, antigen expression on myeloid and blast cells, 2937
acute lymphoblastic, antigen expression on melanoma cell lines, 2456
B cell, therapy by bone marrow transplantation, 2452

Leukemia—*continued*
B lymphocytic, protection against, immunoglobulin immunization and, 970
Friend virus-induced, passive transfer of monoclonal anti-gp70 antibodies, 2363
suppression, cross-reactive monoclonal antibody, 2930
T cells bearing, cytotoxic T cells specific for, 2942
Leukocyte
cell surface molecule, recognition by monoclonal antibody TA-1, 1833
medium conditioned by, promyelocytes, 1120
mononuclear, α interferon effects on immunoglobulin production in, 1215
peripheral blood
analysis of Fc receptors on, 1152
T cell-depleted, 1139
polymorphonuclear, studies of oxidative bursts, 1910
pyrogen, effects of arachidonate metabolism on, 890
Leukocytosis, *Bordetella pertussis*, promoting factor, effect on thymic lymphoepithelial cell association, 2767
Leukotriene B_4, immunologic and ionophore-induced generation, bone marrow-derived mast cells, 1885
Light chain
allotype-defined mRNA for, 442
anti-oxalozone, mRNA sequences, 937
constant regions, spectrotypes of anti-diphtheria toxoid antibodies, 818
extracellular domain of, major histocompatibility complex class II antigens, 808
monoclonal gammapathy, Sjogren's syndrome, 2663
Lipomodulin
fragment, glycosylation-inhibiting factor identification as, 878
phospholipase inhibitory protein, role in immunoregulation by thymocytes, 1930
Lipopolysaccharide
colony-stimulating factor binding to peritoneal exudate macrophages, inhibition by, 2256
lymphokine and, procoagulant activity of macrophage cell lines, effects on, 2750
macromolecular structure, conversion to molecular aggregates with reduced subunit heterogeneity, 2804
macrophage protection from toxicity, metallothionen-inducing agents, 1924
O-antigen, differential complement activation by *Salmonellae*, 1867
peritoneal exudate macrophages treated with, steroidogenesis suppression, 2757
phenol-extracted, B cell subset responses to, 2014
polyclonal B cell activation induced by, suppression with IgG, 2022
Lipoprotein, plasma, inflammation-induced changes in C-reactive proteins and, 1736
Liposome, muramyl dipeptide, monocyte activation by analogues, 1500
Liver
B lineage cell population changes in, neonate, 1616
disease, polymeric IgA estimation in serum, 1176
Lung
lavage fluid, effect on macrophages, 2589
mast cells, activation, 2357
selective recruitment of T lymphocytes to, alveolar macrophage role, 1113
Lupus, renal disease and, retroviral gp70 immune complex, correlation to, 740
Lupus erythematosus
systemic
analysis of vascular lesions, 1699
defective production of interleukin 1 and 2 in, 2651
graft-vs.-host disease, optimal doses of spleen cells for, 2693
impaired immunoregulation in, 1706
thymus-dependent and -independent responses in, 2161
Lymph node, mucocutaneous, syndrome, immunoregulatory T cell abnormalities in, 2002
Lymphoblast
B
antigen expression in Burkitt lymphoma lines, 2448
long-term cell lines, 2113
cell line, adenosine deaminase-deficient, phenotypic reversion, 2866
T, specifically binding monoclonal antibody and, 51
Lymphocyte
activated (G_1), lymphokine regulation, 1770
activation by thiol-derived nucleoside, characterization, 551
allogeneic, interaction, 2241, 2250
allogeneic response, mixed epidermal cell-lymphocyte reaction, 2612
autologous mixed, monocyte subsets inducing, 698
autologous mixed reaction, immunoglobulin secretion during, 1146
B
activated, phospholipid synthesis and, 2568
B2 antigen on Epstein Barr virus-converted lines, 1985
C3b receptors of, C3 effects, 1021
differentiation factor production by T cell hybridoma, 1247
idiotypes on, association with immunoglobulins, 1819
IgG subclass expression by, 671
inhibition of stimulation by primary amines, 91
leukemia, immunoglobulin immunization effects, 970
lineage cell population changes, neonate, 1616
melanoma infiltration, Epstein Barr virus transformation, 2442
mitogen expression, antigen stimulation on, 626
nontransformed, colony growth regulation and, 665
polyclonal activation by immune complexes, 1066
proliferation induction, monoclonal anti-Lyb 2 antibody, 2033
response inhibition by *Trypanosoma cruzi*, 908
binding sites, Epstein Barr virus and C3d, comparison, 1309
blastogenic response, seasonal rhythmicity, 2586
blood, tumor promoter-induced immunoglobulin secretion suppression, 1159
cell surface antigen, LY-22.2, definition and genetics, 946
choriomeningitis virus, genetic control of C1q binding complexes in circulation, 912
C3 receptors on subsets, cellular basis for antibody dependent lymphocyte-mediated cytotoxicity, 2831
cytotoxic, natural killer-like activity, 2952
cytotoxic thymus-derived, heterocliticity, 538
factor activating, effects of arachidonate metabolism on, 890
function, experimental African trypanosomiasis, 2896
functional, pineal gland, 2109
granular, suppressor cell function, 1171
homing patterns, ultraviolet radiation and, 2974
immune, cyclophosphamide and, tumor regression induced by, 2511
interferon production in, protein A effects, 773
intramucosal, phenotype, 558
large granular
growth, immunomodulatory role of interferon, 768
interleukin 2-induced proliferation, 687
large granular clone, natural killer- and T cell-like, 524
membrane, B73.1 antibody antigen interaction on, 2142
mitogenesis, viral inhibition of T cell growth factor, 2372
mixed
reaction, anti-IgD-enhanced, 2534
reaction stimulation, antigen-presenting cells and, 1592
response stimulation, Hodgkin's cells and, 2666
mucosal, small intestine, 2615
natural killer cell activity and, inhibition by granulocytes, 475
natural killer-enriched populations, identification of natural killer soluble cytotoxic factors, 1252
OKT8$^+$, phospholipid binding to, suppressor cell activation, 2271
peripheral blood
natural killer cytotoxic factors released from, 2479
proliferative response, α1 antitrypsin and, 681
skin-directed migration, Sezary syndrome, 2467
phorbol ester-treated, susceptibility to natural killer cytolysis, 2505
phytohemagglutinin-activated, characterization of tumor lysis, 958
primate, monoclonal antibody identification of, 1323
production in bone marrow, regulation, 644
proliferation
inhibition by ultraviolet radiation, 2484
suppression of, 1573, 1580
proliferative responses, induction, cell interactions in, 2093
response inhibition, histamine release and, schistosomiasis, 1376
responsiveness, C-reactive protein effects on, 2121
responsiveness to cytokines, effects of aging, 1754
stimulated, suppressor cell induction factor released by, 2720
subpopulations, immature subset identification in neonate, 1129
subset characterization, reactivity with monoclonal antibody B73.1, 2133
T
activated, migration, 1610
activation, Ia molecules and, 457
blocking by monoclonal antibodies, 2623
chemotactic factor produced by T cell subsets, 2727
cloned, reversible cytolysis, phorbol ester mediation by, 2499
colony growth, dependency on cell soluble factors, 2715
cytolytic, anti-influenza, 2386
cytolytic, blocking of killing mediated by, 2546
cytolytic, clone proliferation, 1545
cytolytic, development to hapten-altered self, 533
cytolytic, helper factors, 756
cytolytic, H-1-specific, 542
cytolytic, monoclonal antibody effects on precursors, 1552
cytolytic, precursor activation, 546
cytolytic, stimulation, 493
cytolytic, suppression of response to hapten-altered self, 2557
cytotoxic, cerebrospinal fluid in mumps meningitis and, 2187
cytotoxic, cross-reactivities, 1439
cytotoxic, development and function, 205
cytotoxic, differentiation factor, 763
cytotoxic, helper cell activity prevention, 56
cytotoxic, helper factors for activation, 2214
cytotoxic, HLA-A2 antigen variants and, 1856
cytotoxic, influenza-specific responses, 2629
cytotoxic, intra- and extra-thymic, 1027
cytotoxic, natural killer depletion and, 1556
cytotoxic, origin of precursors, 1077
cytotoxic, regulation of response against Sendai virus, 1090
cytotoxic, regulatory mechanisms in development, 527
cytotoxic, responses to spontaneous tumors, 2005
cytotoxic, simian virus 40 specific clones, 490
cytotoxic, specificity for self H-2^d antigens, 2429
cytotoxic, vesicular stomatitis virus, 1408
cytotoxic, viral tract infection recovery and, 2908
cytotoxic alloreactive, monoclonal antibody effects on, 1540
cytotoxic hapten-specific, restriction by H-2 products, 2514
defective adenosine-induced suppressor, systemic lupus erythematosus, 1706
function, phorbol myristate acetate and, 1764
genetic control of responses, 637
hydrocortisone acetate and precursor recovery, 33
idiotype-specific H-2-restricted, 1038
IgE-binding factors from, 649
immunodeficiencies, diabetes and, 1723
lymphocyte proliferation induction and, 2093
Lyt-2$^+$ and Lyt-2$^-$, comparison, 2225
marker analysis, response suppression and, 1561
monoclonal antibody specific for, autoimmune encephalomyelitis and, 1503
Nocardia asteroides killing mediated by, 2401
precursors, tolerance induction among, 78
proliferating, surface antigens of, 2794

proliferating and helper, responses to fibrinopeptide B, 2542
proliferation, endotoxin-induced, 1774
proliferation, phorbol myristate acetate and, 2261
proliferation stimulation, 2702
response inhibition by *Trypanosoma cruzi*, 908
responses, cyclosporin A effects, 717
selective recruitment to lung, alveolar macrophage role, 1113
spontaneous γ-interferon, Behçet's disease, 1683
subset characterization, 2075
suppression by C3 fragments, 2605
Thy-1 glycoprotein expression and glycosylation, 1837
T and B, circulating maternal, severe combined immunodeficiency and, 2493
thoracic duct, output, interferon effects on, 2236
Lymphoid organs, mucosal *vs.* non-mucosal, distribution and homing of T cell subsets to, 1097
Lymphoid tissue, mucosal-associated, antibody response regulation during parasitic infection, 435
Lymphokine
arginase activity enhancement, allograft rejection and, 1937
cell line growth and differentiation, regulation by, 2763
eosinophil migration directed by, inhibition by nonsteroid anti-inflammatory drugs, 1356
heat-stable, macrophage phagocytosis enhancement by resident thymocytes, 2195
lipopolysaccharide and, procoagulant activity of macrophage cell lines, effects on, 2750
phorbol myristate acetate contamination, interleukin bioassays and, 1764
regulation of activated (G_1) lymphocytes, prostaglandin E_2-induced inhibition of interleukin 2 production, 1770
release, concanavalin A-activated T cells, comparison, 2225
secretion, Lyt-2 molecular complex relationship to, 1545
sequential action, cytotoxic T cell function, induction and, 2508
suppressor cell induction factor distinct from, 2720
thymosin peptides and, corticogenesis and, 791
Lymphokines
interferon and, regulation of monocyte cytotoxicity, 1220
production by T cell hybridomas, 1231
T cell origin, fibroblast growth modulation by, 1226
Lympholysis
cell-mediated, suppressor T cells for, 2557
defective cell-mediated, cellular basis in atopic dermatitis, 1678
F_1 hybrid cell-mediated, specificity for self H-2^a antigens, 2429
impairment, graft-*vs.*-host disease and interleukin 2 effects, 712
Lymphoma
Burkitt, B lymphoblast antigen expression in, 2448
Epstein Barr virus-negative cell line, B2 antigen on Epstein Barr virus-converted lines, 1985
natural killer and killer cell defects and, low responsiveness to interferon inducers, 1980
Lymphopenia, T, diabetes mellitus and, 1732
Lymphoproliferation, renal disease and, autoimmunity treatment with monoclonal antibody, 1713
Lymphotoxin
production, T cell lines and clones, 2231
synergism between interferon and, enhancement of target cell killing, 518
Lysis
augmented activity, interferon pretreatment of effector cells and, 2964
complement, erythrocyte cell volume and osmotic properties after, 839
HSV-1-infected fibroblasts and K562 erythroleukemia targets, comparison of effectors, 1663
immune
blockade by IgA, 2882
myelin basic protein, 1687
natural killer target cell susceptibility to, interferon-induced inhibition of, 2960
tumor, characterization by phytohemagglutinin-activated lymphocytes, 958

Macrophage
alveolar, pulmonary immune responses, 1113
bone marrow-derived, antigen-induced T cell proliferation and, 661
cell cycle, influence on Fc receptors and antibody-dependent phagocytosis, 1108
cell line
antigen biosynthesis and expression on, 449
FcR-mediated endocytosis of model immune complexes by, 130, 138
cell line like, $P388D_1$, infection with reovirus, 2915
differentiation antigens
expression and induction, 108
expression patterns, 145
Fc-dependent accumulation, experimental glomerulonephritis, 735
Fc-dependent phagocytosis, enhancement by resident thymocytes, 2195
Fc receptors, interferon enhancement of, 1210
hormonal activation of adenylate cyclase in, regulation by guanine nucleotides, 869
isolation of cross-linked IgE-receptor complexes, 1489
maturation, complement secretion, 102
monocyte and, accessory cell function alteration, 2156
peritoneal, C4 biosynthesis by, 834
peritoneal exudate
colony-stimulating factor binding to, lipopolysaccharide inhibition, 2256
lipopolysaccharide-treated, suppression of hormone-induced steroidogenesis and, 2757
priming activity, γ interferon and, 2011
procoagulant activity
cell-mediated immunity and, 2743
lymphokine and lipopolysaccharide effects on, 2750
prostaglandin E and thromboxane synthesis in, stimulation by purified C3b, 2861
protection from lipopolysaccharide cytotoxicity, metallothionen-inducing agents, 1924
receptor, alveolar lining material effect on, 2589
release of lymphokines acting on, T lymphocytes and, 2225
requirement, lymphocyte proliferation induction and, 2093
supernatant, mesangial cell proliferation suppression by, 1790
suppressor, generation kinetics, 1580
Malaria, merozoites, protein on, 2886
Marek's disease
virus serotypes
monoclonal antibodies reactive with tumor-associated antigen, 1007
monoclonal antibodies specific for, 1003
Melanoma
antigen associated with, high molecular weight, 1467
infiltration by B cells, Epstein Barr virus transformation, 2442
malignant cell lines, acute lymphoblastic leukemia antigen expression on, 2456
primary and autologous metastatic lesions, antigenic heterogeneity of, 1462
Membrane, MBL-2 reconstituted, cytolytic T lymphocyte stimulation and, 493
Meningitis, mumps, cerebrospinal fluid in, clonal analysis of T lymphocytes, 2187
8-Mercaptoguanosine, lymphocyte subsets responsive to, 551
Merozoite, malaria, protein on, 2886
Metallothionen, agents inducing, protection against lipopolysaccharide cytotoxicity, 1924
Microfluorometry, flow, dual fluorescence, Fc receptor analysis, 1152
β_2-Microglobulin
modification of conformation of, HLA heavy chains, 1432
paucity of, neuroblastoma cell lines, 2467
Milk, human, IgG4 and, 1654
Mitogen
antigen-induced activity, schistosomiasis mansoni, 2891
B lymphocyte stimulation by, antigen expression, 626
polyclonal, IgG subclass expression and, 671
proliferation induced by, inhibition by *Trypanosoma cruzi*, 908
responsiveness, decrease after epinephrine administration, 694
T cell, spleen cells and, skin allograft effects, 2343
T cells stimulated by
characterization of B cell growth factor, 1241
cyclosporin A and Tac antigen expression of, 2737
Mitogenesis
lymphocyte, viral inhibition of T cell growth factor, 2372
T cell, cell line differences in development of, 2528
Monocyte
activation by liposome-encapsulated muramyl dipeptide analogues, 1500
antigen-presenting capabilities of, correlation with Ia determinant, 706
antigens specific for, expression in promyelocytic cell lines, 1120
differentiation antigens, expression patterns, 145
functional subsets of, monoclonal antibodies and, 698
granulocyte and, colony-stimulating activity, synthesis and secretion, 800
macrophage and, accessory cell function, alteration, 2156
peripheral blood, cytolytic activity potentiation of, 1220
prostaglandin release, C3 stimulation of, 874
Monosaccharide, interleukin 2, T cell cytotoxicity suppression reversal by, 2200
mRNA
allotype-defined, immunoglobulin heavy and light chains, 442
light and heavy chain sequences, anti-oxazolone, 937
Mucocutaneous lymph node syndrome, immunoregulatory T cell abnormalities in, 2002
Mucosal secretions, free secretory component levels in, variations, 1330
Mumps, meningitis, cerebrospinal fluid in, clonal analysis of T lymphocytes, 2187
Muramyl dipeptide, liposome-encapsulated analogues, monocyte activation by, 1500
Muscle, smooth, isolated cells, C5a effects on, 1997
Mutant
B6.C-H-2^{bm12}, H-Y antigen and, nonresponsiveness, 655
H-2, Sendai virus-specific cytotoxic T lymphocyte, analysis, 1090
Mutation, irradiation, effects on natural resistance to marrow grafts, 484
Mycobacterium tuberculosis, suppressor cell activating factor released by, 2266
Myelin
basic protein
detection of autoimmune cells proliferating to, 1205
encephalitogenic activity of small form, 2183
epitopes of peptide 43-88 of, 2180
immune lysis, 1687
relapsing experimental allergic encephalomyelitis induced by, 1024
glycoprotein associated with, reaction with M-proteins, neuropathy and, 2496
Myeloma
IgE synthesis, inhibition by T cells, 1567
IgG2a, protein, cross-reactivity of suppressor T cells specific for, 1498
variant immunoglobulins, Igh-1^a allotypic determinant localization with, 1967
Myeloperoxidase, hydrogen peroxide and, IgG aggregation, 1918

Neonate
B lineage cell population changes, liver and spleen, 1616
lymphocyte subpopulations, subset identification, 1129
thymectomy, acceleration of autoimmunity, 1200
tolerance to phosphorylcholine, idiotype shifts, 590
Nephropathy, polymeric IgA estimation in serum, 1176
Neuraminidase
galactose oxidase and, lymphoid cells treated with, T lymphocyte activation and, 2702
influenza virus, interaction with Fab fragment, equilibrium constant, 1313
Neuroblastoma, cell line, HLA-A, B, C and β_2-microglobulin paucity on, 2471

Neuropathy, myelin-associated glycoprotein, M-proteins reacting with, 2496
Neutropenia, vinblastine-induced, late phase reactions, effects on, 2837
Neutrophil
  antibody-dependent cell-mediated cytotoxicity of, activation by colony-stimulating factors, 795
  complement-mediated binding to, soluble antibody/dsDNA immune complexes, 2656
  complement receptor capping on, group A streptococcal cell walls, 1674
  depletion, late phase reactions, effects on, 2837
  exposure to chemotactic factors, respiratory burst enzyme potentiation, 2316
  formyl peptide chemotactic receptor modulation on, anti-inflammatory effects of prostaglandin E_1, 1495
  inflammatory mediator release, regulation, 850
  oxidative metabolism, locomotion, degranulation, and membrane changes, histamine modulation of, 1902
  polymorphonuclear leukocyte oxidative bursts, flow cytometric studies, 1910
  tripeptide- or Ca^{2+} ionophore A23187-stimulated, phosphatidoylinositol and arachidonic acid, Ca^{2+} effects, 2849
  zymosan-stimulated, origin of chemiluminescence in, 2324
Newcastle disease, virus, delayed hypersensitivity, interferon and, 2392
Nippostrongylus brasiliensis, mucosal-associated lymphoid tissues of, heterologous antibody response regulation, 435
Nocardia asteroides, T cell-mediated killing of, 2401
Nonsteroid anti-inflammatory drugs, arachidonic acid, effects on lymphokine-directed eosinophil migration, 1356
Nucleoside
  guanine, immunopotentiation by, 2580
  thiol-derivatized, lymphocyte activation by, 551
Nucleotide, guanine, regulation of hormonal activation of adenylate cyclase, 869

Oligomer
  IgG
    internalization, 130
    self-aggregating, endocytosis of, 138
Ontogeny
  antigen-presenting cells, mixed lymphocyte reaction stimulation, thymus, 1592
  B cell distribution and, experimental, 619
  concanavalin A and phytohemagglutinin responses, blood cells in major histocompatibility complex compatible lines, 2528
  terminal deoxynucleotidyl transferase synthesis, thymocytes, 1627
Opsonization, requirements for IgG activity, type 6 streptococci, 896
Orchitis
  experimental allergic
    immunopathology of, 2675
    isolation of aspermatogenic polypeptide, 2683
Oxazolone, idiotype structure, anti-oxazolone hybridomas and, 937
Oxidative metabolism, altered, selenium-deficient granulocytes, 2856

Pancreas, lymphocytic infiltration, diabetes mellitus and, 1732
Papain, target cell treatment, cytolytic T lymphocyte-mediated killing, blocking of, 2546
Paralysis, transient, herpesvirus-induced, prevention, 2000
Parasitemia, non-antibody-mediated control, acute experimental Chagas' disease, 1953
Peanut agglutinin, thymocyte subpopulations, cellular protein synthetic responses with dexamethasone, 115
Peptide
  43-88, myelin basic protein, epitopes of, 2180
  anaphylatoxic, induction of thromboxane release by, 1345
  chemotactic activation of stimulus-dependent cytotoxicity, regulation of neutrophil inflammatory mediator release, 850
  chemotactic stimulation induced by, granulocyte activation by endotoxin, 863
  CNBr cleavage, influenza viral hemagglutinin, T lymphocyte stimulation, 2386
  synthetic, hepatitis B surface antigen, epitopes, 1947
  thymosin, corticogenesis and, 791
Peptide spacer, azobenzenearsonate-*N*-acetyl-L-tyrosine-specific help, 586
Peritoneal exudate
  lipopolysaccharide-treated macrophages, steroidogenesis suppression, 2757
  macrophages, colony-stimulating factor binding to, lipopolysaccharide inhibition, 2256
Phagocyte
  differentiation antigens, monocyte-macrophage expression patterns, 145
  mononuclear, stimulation of prostaglandin release by C3 cleavage products, 874
Phagocytosis
  antibody-dependent, macrophage cell cycle influence on, 1108
  Fc-dependent, macrophage, enhancement by resident thymocytes, 2195
Phenol, lipopolysaccharide extraction, B cell subset responses to, 2014
Phenotype
  cell surface antigens, expression by suppressor T cell hybridomas, 565
  Ly-2 and Thy-1, anti-hapten cytotoxic clones, 2046
  Lyt-2 and Thy-1, gut intramucosal lymphocytes and, 558
  T cell activity differences, *Ir* gene control of immune responses to insulins, 2062
  T cell subsets, colony growth regulation and, 665
Phorbol ester
  12-*O*-tetradecanoylphorbol-13-acetate, lymphocytes treated with, natural killer lysis and, 2505
  reversible cloned T lymphocyte cytolysis, mediation by, 2499
  T cell line susceptibility to, 2732
Phorbol myristate acetate
  cloned T cell proliferation and, 2261
  T lymphocyte function and, interleukin assays, 1764
Phosphatidylethanolamine, binding to lymphocytes, suppressor cell activation and, 2271
Phosphatidylinositol
  binding to lymphocytes, suppressor cell activation and, 2271
  response in neutrophils, Ca^{2+} role, 2849
Phosphocholine
  antibody response specific for, Lyb-5^+ and Lyb-5^- B cell roles, 2574
  protein and, conjugate, resistance to *Streptococcus pneumoniae* induced by, 2871
Phospholipase inhibitory protein, lipomodulin, immunosuppression and, 1930
Phospholipid
  binding to OKT8$^+$ lymphocytes, suppressor cell activation by, 2271
  liposomal, antibodies reactive with, trypanosomiasis, 1390
  synthesis, activated B lymphocytes and, 2568
Phosphorylcholine, neonatal tolerance to, idiotype shifts caused by, 590
Photoallergic contact dermatitis, induction, suppressor cells and, 2099
Photoimmunotherapy, monoclonal antibody-hematoporphyrin, treatment with tumor-specific conjugates, 1473
Phytohemagglutinin
  lymphocytes activated with
    characterization of tumor lysis, 958
    ontogeny of blood cell responses, major histocompatibility complex compatible lines, 2528
Pineal gland, functional lymphocytes in, 2109
Plasma, lipoproteins, inflammation-induced changes in C-reactive proteins and, 1736
Plasmodium knowlesi, malaria merozoites, protein on, 2886
Pollen, *Ambrosia elatior*, antigens of, 727
Poly-L-glutamic acid, *p*-azobenzenearsonate and, conjugate, immune response to, 573
Polymorphism, structural, Ia antigens, wild and inbred mice, 1280
Polypeptide
  aspermatogenic, isolation, experimental allergic orchitis and, 2683
  22,000-dalton Ia, biochemical characterization, 1268
Polyribonucleotide, polyinosinic-polycytidylic, interferon induction and thoracic duct lymphocyte output, 2236
Polysaccharide, pneumococcal, antibody response, T cell regulation, 19
Precursor
  cytotoxic T lymphocyte, maturation, alloimmunization and, 2056
  frequency, anti-hapten cytotoxic clones, 2046
Procoagulant
  activity
    macrophage, cell-mediated immunity and, 2743
    macrophage, lymphokine and lipopolysaccharide effects, 2750
Proliferation, B cell, role of linked recognition in, 614
Promyelocyte, differentiation, expression, and cytotoxicity, leukocyte-conditioned medium, 1120
Prostaglandin, release, stimulation by C3 cleavage products, 874
Prostaglandin E
  natural killer suppression induced by, cyclic AMP as mediator of, 1350
  synthesis, stimulation by purified C3b, 2861
Prostaglandin E_1, anti-inflammatory effects, modulation of neutrophil function, 1495
Prostaglandin E_2, interleukin 2 production inhibition induced by, lymphokine regulation of activated (G_1) lymphocytes, 1770
Protein
  activities inducing, γ interferon preparations, 1019
  cell surface, detection by antisera to antigen-binding factor, 2083
  cellular, dexamethasone-induced synthetic responses, 115
  C-reactive
    effects on lymphocyte responsiveness, 2121
    inflammation-induced changes in, 1736
  Epstein Barr virus-specific, immunoprecipitation of, 919
  gp70, immune complex, correlation to renal disease, 740
  IgG2a myeloma, cross-reactivity of suppressor T cells specific for, 1498
  malaria merozoites, 2886
  M-protein, reaction with myelin-associated glycoprotein, neuropathy and, 2496
  myelin basic
    detection of autoimmune cells proliferating to, 1205
    encephalitogenic activity of small form, 2183
    epitopes of peptide 43-88, 2180
    immune lysis, 1687
    relapsing experimental allergic encephalomyelitis induced by, 1024
  phosphocholine and, conjugate, resistance to *Streptococcus pneumoniae* induced by, 2871
  phospholipase inhibitory, lipomodulin, immunosuppression and, 1930
  protein A, interferon production in lymphocytes and, 773
  Toxoplasma gondii, purification, 2407
Proteinase, egg, *Schistosoma mansoni*, 1
Proteins, regulatory, H, surface-dependent modulation of C5 cleavage, 2821
Prothymocyte, postirradiation regenerating thymuses, T cell differentiation model, 121
Pteridines, marker for activated T cells, 1047
Pyrimidinone, 5-halo-6-phenyl, cancer therapy and interferon induction, natural killer induction and, 965
Pyrogen, leukocytic, antibody against, immunoglobulin-secreting cell generation by, 2708

Radiation
  bone marrow chimeras induced by, thymic antigen-presenting cells and, 2525
  mutation and, effects on natural resistance to marrow grafts, 484
  sublethal whole-body, T cell responses, effects on, 24
  ultraviolet
    alterations in lymphocyte homing patterns and, 2987
    cytotoxic T cell sensitization inhibition by, 2071
    inhibition of natural killer activity and lymphocyte proliferation, 2484
    UV-B, epidermal cell antigen-presenting capacity impairment, 1586
    UVB, photoallergic contact dermatitis and, suppression, 2099
Radioimmunoelectrophoresis, crossed, ragweed-allergic sera, 727
Ragweed, *Ambrosia elatior* pollen, antigens of, 727

Reagent
haptenic sulfhydryl, lympholytic responses against cells modified with, 1506
Schistosoma mansoni microsomal antigens, purification, 1359, 1366
Receptor
anti-H-Y, delayed-type hypersensitivity responses, 1604
anti-T cell, antibody production, 1033
C3, fragments, cellular basis for antibody-dependent lymphocyte-mediated cytotoxicity, 2831
C3b
B lymphocyte, C3 effects on, 1021
expression, 1668
complement, capping on neutrophils, 1674
C1Q, binding to gingival fibroblasts, 1871
Epstein Barr virus, Raji cells, 1303, 1309
erythrocyte, differentiation of cell populations and, 162
Fc
analysis on peripheral blood leukocytes, 1152
macrophage, interferon enhancement of, 1210
macrophage cell cycle influence on, 1108
formyl peptide chemotactic, prostaglandin E_1 effects, neutrophil, 1495
heterogeneity, heteroclitic cytotoxic lymphocyte clone, 538
IgE and, cross-linked complexes, isolation from macrophages, 1489
interleukin 2
inhibition by monoclonal antibody, 51
membrane antigen distinct from, 747
macrophage, alveolar lining material effect on, 2589
membrane-associated complement, CR1, 1876
re-expression and regulation, capping kinetics and, 38
T cell, self major histocompatibility complex gene products, 1512
T cell growth factor, cyclosporin A and Tac antigen expression of, T cells and, 2737
Receptor complex, EBV/C3, B lymphoblast antigen expression in lymphoma lines, 2448
Red blood cell, *see* Erythrocyte
Reovirus, antibody-mediated infection with, P388D, cell line, 2915
Respiratory burst enzyme, potentiation, neutrophil exposure to chemotactic factors, 2316
Response
antibody, derivatized guanine nucleosides as adjuvant for, 2580
cellular protein synthetic, dexamethasone and, 115
immune
anaphylatoxin-mediated regulation of, 1257
9-β-D-arabinofuranosyladenine and, 829
p-azobenzenearsonate-poly-L-glutamic acid conjugate, 573
behaviorally conditioned suppression by anti-lymphocyte serum, 2117
cellular, Epstein Barr virus and, 2127
genetic regulation of, hepatitis B surface antigen, 1395, 1401
impaired, aging and, 1754
induction by schistosome granuloma macrophages, 2413
insulins, *Ir* gene control of, 2062
pulmonary, alveolar macrophages in, 1113
regulation by I-J gene products, 1274
regulation to tumor antigen, 997
role of self carriers, 86
schistosomiasis mansoni, 2891
thymus-dependent and -independent, lupus and, 2161
lymphocyte blastogenic, seasonal rhythmicity, 2586
Rheumatoid factor, subsets of human autoantibody-producing B cells, 162
Ribonucleoside, guanine, C8-derivatized, T cell-replacing activity of, 2042
Ricinus communis, agglutinin, inhibition of OKT4 and OKT8 binding by, 1646

Salmonellae, differential complement activation by, lipopolysaccharide O-antigen and, 1867
Salmonella typhimurium, natural and antibody-dependent cell-mediated activity against, peripheral and intestinal lymphoid cells, 903
Schistosoma mansoni
egg proteinase, monoclonal antibody to, 1
fibroblast stimulation in schistosomiasis, 1371
microsomal antigens, purification, 1359, 1366
Schistosomiasis
fibroblast stimulation in, 1371
granuloma macrophages, immune response induction by, 2413
immune responses during, production of mitogenic factor activity in, 2891
modulation of host response, immunosuppression by histamine, 1376
Secretion, immunoglobulin, B cell proliferation and, 2597
Secretory component, levels in mucosal secretions, variations, 1330
Selenium, deficiency, granulocytes, 2856
Sensitivity, contact, 4-hydroxy-3-nitrophenyl acetyl, 97
Serotherapy, monoclonal antibody, hepatocarcinoma model for, 1451
Serum
anti-Epstein Barr virus, immunoprecipitation of proteins specific for, 919
antilymphocyte, behaviorally conditioned immunosuppression by, 2117
hepatitis B e antigen in, immunochemical structure, 2903
hyperimmune, suppressor T cell induction by monoclonal anti-idiotope antibody, 2079
low molecular weight C3-bearing immunoglobulin, generation in, 2775
Serum amyloid P-component, strain dependence, response to inflammation and, 885
Sezary syndrome, skin chemotactic response in, skin-directed migration of peripheral blood lymphocytes, 2467
Sjogren's syndrome, monoclonal gammapathy in, 2663
Skin
allograft, enhanced histamine and histamine-producing cell-stimulating factor production, 2343
chemotactic response, Sezary syndrome, 2467
late phase reactions, effect of vinblastine-induced neutropenia on, 2837
Spleen
B lineage cell population changes in, neonate, 1616
cytotoxic T lymphocyte precursor regeneration, sublethal dose of cyclophosphamide, 1077
enhancement of binding to, red blood cell, 1336
helper factors derived from, cytotoxic T cell activation and, 2214
lupus-like graft-*vs.*-host disease, optimal doses, 2693
polyclonal B cell activation suppression, heat-aggregated IgG, 2022
response to T cell mitogens, skin allografts and, 2343
stimulator cells, anti-IgD-enhanced mixed lymphocyte reaction, 2534
T cell cytotoxicity suppression by, reversal by monosaccharides and interleukin 2, 2200
Splenocyte, "endotoxin-unresponsive," lipopolysaccharide responsiveness in, 2804
Staphylococcus aureus
immunoadsorption to, Langerhans cell enrichment by, 2008
protein A, interferon production in lymphocytes and, 773
Steroidogenesis, adrenocorticotropic hormone-induced, suppression by macrophage product, 2757
Streptococcus
group A cell walls, complement receptor capping on neutrophils by, 1674
type 6 group A, opsonic IgG for, 896
Streptococcus pneumoniae
resistance mechanism, complement-mediated killing, 845
resistance to, phosphocholine-protein conjugate-induced, 2871
Streptozotocin, autoimmune diabetes induced by, genetic control of, 1719
Sulfhydryl reagent, *see* Reagent
Superoxide anion, production induction, lymphokine-induced cell differentiation, 2763
Suppression
antigen-specific and -nonspecific pathways, mediation by distinct T cell subpopulations, 1061
B cell leukemia, therapy by bone marrow transplantation, 2452
bone marrow, T cell-derived B cell growth and differentiation factors, 2502
carcinogenesis, spontaneous hypertension and T cell depression, 501
cytolytic T lymphocyte response to hapten-altered self, suppressor T cells, 2557
graft-*vs.*-host-associated, cytotoxic T lymphocyte responses, 1561
hormone-induced steroidogenesis, macrophage product, 2757
humoral immunity, herpesvirus-induced transient paralysis, prevention, 2000
Idl-104E specific, 86
idiotype, mechanisms of, 596
immunoglobulin secretion, tumor promoter-induced, 1159
inducer subset demonstration, anti-T cell antibodies, 157
isotype-specific, IgA, 521
leukemia, cross-reactive monoclonal antibody, 2930
lipopolysaccharide-induced polyclonal B cell activation, heat-aggregated IgG, 2022
lymphocyte proliferative responses
characterization, 1573
suppressor macrophage generation, 1580
mesangial cell proliferation, macrophage supernatants and, 1790
mitogen-induced blastogenesis, filariasis, 1381
natural killer activity
β-estradiol effects, 974
peritoneal cells, 1974
photoallergic contact dermatitis, UVB radiation and, 2099
Pichinde virus-specific cell-associated, swelling and, 925
prostaglandin E-induced, cyclic AMP in natural killer cells, 1350
release from, immunization and, 7
T cell, cyclosporin A effects, 1071
T cell cytotoxicity, spleen cells, 2200
T cell function, differential inhibition of, 2623
T lymphocyte functions, C3 fragments, 2605
T lymphocyte generation, systemic lupus erythematosus and, 1706
Suppressor factor
antigen-specific, detection by antisera to antigen-binding factor, 2083
GT-specific, composition, 1274
IgE class-specific, IgE production inhibition by, 1056

Teratocarcinoma, H-2 antigens, splenic cell regulation of, 2969
Terminal deoxynucleotidyl transferase, synthesis, clonal proliferation and, thymocytes, 1627
Tetanus
toxoid, booster immunization, idiotypic anti-idiotypic interactions, 1634
toxoid-specific T cell line, antigen-specific and polyclonal immunoglobulin production, 1164
12-*O*-Tetradecanoylphorbol-13-acetate
immunoglobulin suppression induced by, blood lymphocytes, 1159
lymphocytes treated with, susceptibility to natural killer cytolysis, 2505
T lymphoid lines induced by, deoxyguanosine resistance acquisition by, 1622
Thoracic duct, lymphocyte output, interferon effects on, 2236
Thromboxane
induction of release from macrophages, anaphylatoxic peptide C3a-evoked, 1345
synthesis, stimulation by purified C3b, 2861
Thymectomy, neonatal, thymic regulation of autoimmunity, 1200
Thymocyte
activating factor, glomerular mesangial cells, 1796
immunoregulation by, lipomodulin and, 1930
murine, phenotypic and functional properties, 33
peanut agglutinin positive and negative, cellular protein synthetic responses with dexamethasone, 115
resident, macrophage phagocytosis enhanced by, 2195
terminal deoxynucleotidyl transferase synthesis in, clonal proliferation unlinked to, 1627
Thymus
abnormal epithelium, severe cellular immunodeficiency and, 1182
antigen-presenting cells, self-Ia recognition and, 2525
antigen-presenting cells in, ontogeny, 1592

Thymus—*continued*
antigens dependent on, linked recognition in B cell proliferation to, 614
antigens independent of, purification and response to, 607
autoimmunity regulation, disease acceleration by neonatal thymectomy, 1200
dependent and independent antigens, lupus and, 2161
dysfunction, diabetes and, 1195
epithelial and lymphocytic components, glycosaminoglycan biosynthesis, 1848
lymphoepithelial cell association, *Bordetella pertussis* leukocytosis-promoting factor, effects on, 2767
postirradiation regenerating, prothymocytes in, T cell differentiation model, 121
T cell colonies from, growth and characterization, 45
thymic nurse cell, identification and localization, 2348
Tissue, natural killer distribution, anti-Leu-7 monoclonal antibody and, 2149
TNP, anti-self, monoclonal antibody effects on, 1540
Tolerance
immune response and, role of self carriers in, 86
induction, hapten-specific T lymphocyte precursors, 78
Toxoplasma gondii, membrane protein of, purification, 2407
Transplant
allogeneic, tumor, induced rejection by immune alteration, 951
bone marrow, B cell leukemia therapy by, 2452
Trinitrophenyl, specific cytotoxic T precursor cells, immunization results, 7
Tripeptide, neutrophils stimulated by, Ca^{2+} role, phosphatidylinositol and arachidonic acid, 2849
Trypanosoma cruzi, inhibition of T and B cell responses by, 908
Trypanosoma rhodesiense, infection, anti-phospholipid antibodies in, 1390
Trypanosomiasis
African, lymphocyte function in, 2896
anti-phospholipid antibodies in, 1390
Tryptase
mast cell
C3a anaphylatoxin generation from C3 by, 1891
high molecular weight kininogen inactivation by, 2352
Tumor
allogeneic transplant, induced rejection by immune alteration, 951
antigen, regulation of immune response to, 997
B cell, cytotoxic anti-idiotype effects on, 970
cell killing, macrophage priming activity of γ interferon, 2011
cell soluble factors, T cell colony growth dependent on, 2715
immunity specific for, augmentation by semiallogeneic cell hybrids, 2982
inhibition of growth, monoclonal anti-I-J antibodies, 506
lysis, characterization by phytohemagglutinin-activated lymphocytes, 958
mammary, virus, gp52-cross-reactive antigen expression, 2368
metastasis, β-estradiol effects, 974
Moloney murine sarcoma virus-induced, secondary cytotoxic response, 1447
monoclonal antibody-hematoporphyrin photoimmunotherapy, 1473
promoter
12-*O*-tetradecanoylphorbol-13-acetate, 1159
T cell line susceptibility to, 2732
regression, cyclophosphamide and immune lymphocyte combination therapy, 2511
spontaneous, cytotoxic T lymphocyte responses to, 2005
surface antigen associated with, Marek's disease, monoclonal antibody reactive with, 1007
tumor-specific antigens on, dissection with T cell clones, 2461
L-Tyrosine-*p*-azophenyltrimethylammonium, suppressor T cells induced by, sequential appearance of, 2519

Vascular lesions, systemic lupus erythematosus, analysis, 1699
Vesicle, lipid and myelin, immune lysis of myelin basic protein and, 1687
Vinblastine, neutropenia induced by, late phase reactions, effects on, 2837
Viral tract, infection, recovery specificity by cytotoxic T cells, 2908
Virus
anti-Epstein Barr serum, immunoprecipitation of proteins specific for, 919
choriomeningitis, lymphocytic, genetic control of C1q binding complexes in, 912
Epstein Barr
B2 antigen, 1985
B cell lines derived from, severe combined immunodeficiency, 2493
B cells transformed by, chlamydia antibody production, 2899
B lymphocytes transformed by, 2442
cells infected by, limiting dilution analysis, 1640
cellular immune response to, 2127
receptor on Raji cells, 1303, 1309
Friend, leukemia, passive transfer of monoclonal anti-gp70 antibodies, 2363
growth, immune ascitic fluid and monoclonal antibody effects on, 79
herpes simplex
fibroblasts infected with, lysing with effectors, 1663
glycoprotein, delayed hypersensitivity and protection induced by, 1413
monoclonal antibodies against, 1943
influenza
cytolytic T lymphocytes and, 2386
cytotoxic T lymphocytes specific for, defective production, 2629
recovery specificity by cytotoxic T cells, 2906
influenza A/PR/8/34, helper T cell for hemagglutinin of, 2379
lymphocyte mitogenesis, inhibition by, 2372
mammary tumor, gp52-cross-reactive antigen expression, B cell subset, 2368
Marek's disease, monoclonal antibodies specific for, 1003
Moloney-murine sarcoma, cytolytic T lymphocyte stimulation and, 493
Moloney murine sarcoma, tumors induced by, 1447
Newcastle disease, interferon and delayed hypersensitivity, 2392
Pichinde, cell-associated suppression specific for, 925
Sendai, cytotoxic T lymphocyte response against, regulation, 1090
simian virus 40
transformed C3H fibroblasts, gene defect in, 2418
transplantation rejection antigen demonstration, 490
T cell leukemia, cytotoxic T cells specific for, 2942
vaccinia, interferon effects on thoracic duct lymphocyte output, 2236
vesicular stomatitis, cytotoxic T lymphocytes reactive with, 1408

Wheat germ agglutinin, inhibition of OKT4 and OKT8 binding by, 1646

Zymosan, opsonized, neutrophils stimulated by, origin of chemiluminescence in, 2324